Podcasts about ssris

In this solo episode of Vee the People, Vee gets real and a little more unfiltered than usual. She talks openly about her experience with anxiety — what it actually feels like day-to-day, how it's shown up in her life, and what it's been like navigating SSRIs. She also dives into imposter syndrome and that all-too-familiar feeling of questioning yourself, even when you know you shouldn't. Of course, it wouldn't be Vee without a little comfort mixed in — she shares the TV shows she's been loving lately and how they've become her go-to escape when her brain won't slow down. And after being away, she talks about coming home to her cats and the kind of peace that only those small, familiar moments can bring. It's a laid-back, honest episode about mental health, overthinking, and finding comfort in the little things — just Vee being Vee on Vee the People.

Taking an SSRI or SNRI is considered the gold standard for PPPD treatment. But is it? Honestly, it depends. (And you know we're gonna take a look at the research!) A lot of people are really sensitive to medication or simply don't want to take it. And while you don't need to take medication—it could be helpful. It could also not be helpful. To get to the best answer for your unique situation, it involves considering your specific wants and needs, goals, and timeline. In this episode, we'll dig into: What the research says about the efficacy of SSRIs and SNRIs for treating PPPD Why SSRI/SNRIs are being considered as a treatment tool to begin with The relationship between our nervous system and dizziness Real world examples of how your brain tries to protect you New module that's coming to Vestibular Group Fit this year How an SSRI or SNRI can help treat PPPD Things to do aside from meds to help regulate the nervous system The first step of better managing PPPD No, you can't think your way out of chronic dizziness, but your brain and the way you're thinking about things does have a big impact on your vestibular disorder. There is no right or wrong way to go about treating PPPD, vestibular migraine, or any other vestibular disorder. And… it's expected for things to be changing and shifting as you try treatment methods, learn new things, or other goals or priorities force you to change your plan a bit. Things can get better! I see it every week inside Vestibular Group Fit! We'd love to see you in there. Links Mentioned: Vestibular Group Fit (code GROUNDED at checkout for 15% off!): https://thevertigodoctor.com/vestibular-group-fit Citations: Maximilian Maywald, Oliver Pogarell, Susanne Levai, Marco Paolini, Nadja Tschentscher, Boris Stephan Rauchmann, Daniela Krause, Sophia Stöcklein, Stephan Goerigk, Lukas Röll, Birgit Ertl-Wagner, Boris Papazov, Daniel Keeser, Susanne Karch, Agnieszka Chrobok,Neurofunctional differences and similarities between persistent postural-perceptual dizziness and anxiety disorder,NeuroImage: Clinical,Volume 37,2023,103330,ISSN 2213-1582, https://doi.org/10.1016/j.nicl.2023.103330. (https://www.sciencedirect.com/science/article/pii/S2213158223000190) Bingel U, Wanigasekera V, Wiech K, Mhuircheartaigh RN, Lee MC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: Imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3 doi: 10.1126/scitranslmed.3001244. Those with chronic pain undergoing pain reprocessing theory found relief in symptoms but also changes in brain activity (citation here) Free Resources: ⁠The 4 Steps to Managing Vestibular Migraine: https://thevertigodoctor.myflodesk.com/cb5js0y78n ⁠The PPPD Management Masterclass⁠: https://thevertigodoctor.myflodesk.com/new-pppd ⁠What your Partner Should Know About Living with Dizziness⁠: https://thevertigodoctor.myflodesk.com/partnership ⁠The FREE Mini VGFit Workout⁠: https://thevertigodoctor.myflodesk.com/minifit ⁠The FREE POTS – safe Workouts⁠: https://thevertigodoctor.myflodesk.com/pots Connect with Dr. Madison (@TheVertigoDoctor): https://instagram.com/thevertigodoctor Work with Dr. Madison: For 1:1 Vestibular Rehabilitation Therapy, email madison@thevertigodoctor.com Otherwise, I'll see ya in Vestibular Group Fit! Connect with Dr. Jenna (@dizzy.rehab.therapist): https://www.instagram.com/dizzy.rehab.therapist/ Learn about the Oak Method: http://thevertigodoctor.com/why-vestibular-group-fit Love what you heard?Consider leaving a review on your favorite podcast platform to help us reach more vestibular warriors like you! This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— ssri vs snri, ssri for PPPD, snri for PPPD, medication for pppd, chronic dizziness, mindset shift, mindset and chronic illness, PPPD treatment options, dizzy anxious dizzy cycle, PPPD and anxiety, neuroplasticity, nervous system and dizziness, chronic pain, vestibular migraine and PPPD

He details natural hormone support, SSRIs risks, exercise benefits, tryptophan for sleep, and brain-boosting antioxidants. #HormoneHealth #NaturalMoodSupport #NeuroProtection #LongevityMovement

Meet the Fantastic—and Controversial—Dr. David Healy Psychiatric Drug Companies-- What Are They NOT Telling Us? Today, we are thrilled to interview the famed and courageous Dr. David Healy. I have admired his work for many years, but never imagined I'd have the chance to meet him and chat with him. First things first. You may know Dr. David Healy for some of his highly controversial books, like "The Antidepressant Era," "Let Them Eat Prozac," and "Pharmageddon." But who is he, really? According to AI, Dr. David Healy is a prominent Welsh psychiatrist, psychopharmacologist, and critic of the pharmaceutical industry known for his research on antidepressants, their links to suicide, and exposing industry practices like ghostwriting and disease-mongering, operating through initiatives like RxISK.org to promote drug safety. He has a long history of challenging Big Pharma, facing academic backlash (like losing a University of Toronto post) for his views, and serving as an expert witness in legal cases involving psychotropic drugs, advocating for greater transparency and patient safety.  Healy initially worked with pharmaceutical companies, gaining firsthand knowledge of how SSRIs were marketed despite their trial weaknesses, focusing on the oversimplified serotonin hypothesis. He then became a vocal critic, highlighting issues like ghostwriting articles and manipulating academic opinion to sell drugs, leading to conflicts with industry-funded institutions. He founded RxISK.org, a platform for patients to report adverse drug reactions, aiming to make medicines safer. His strong stance (on research linking SSRI antidepressants to increased suicidal thoughts and urges) led to intense and corrosive controversy, including losing a professorship at the University of Toronto (though later settled as a visiting role) and harassment, noted here and here. In recent years, he has acted as an expert witness in cases involving drug-related suicides and homicides, bringing issues to regulators.  In essence, Dr. David Healy is a significant, often controversial, figure dedicated to drug safety, academic integrity, and patient awareness in psychiatry, challenging established narratives and industry power.  Taking a deeper dive, AI has added this critically important information: David Healy has discussed numerous examples of conflicts of interest that mainly involve the influence of the pharmaceutical industry on medical research, publication, and practice.  Key examples he has highlighted include: Ghostwriting of Articles: Pharmaceutical companies hire medical communication firms to draft research articles or reviews, and then get prominent academics or clinicians to put their names on the papers as the sole or primary authors, a practice known as ghostwriting. The named authors often have little to no involvement in the actual research or writing. Hiding or Misrepresenting Data: Drug companies have concealed unfavorable data or miscoded raw data on drug risks, such as the link between antidepressants and suicidal acts. This manipulation can make a drug appear safer or more effective than it actually is. Biased Clinical Trial Design: Healy notes instances where clinical trials are designed with "tricks," such as using inadequate or excessive doses of comparison medications to make the company's own drug look superior. Marketing-Driven Education: A large portion of continuing medical education (CME) classes for doctors are sponsored by industry. Healy argues this leads to a bias in the information presented to doctors, with an emphasis on the benefits of brand-name drugs rather than an objective assessment of all treatment options. Gifts and Payments to Physicians: Drug companies spend billions annually on marketing directed at doctors, including free samples, sales visits, and small non-educational gifts or lunches. Healy points out that while many doctors believe these gifts don't affect their own prescribing, studies show they influence prescribing patterns and create subtle biases. Industry Influence on Academia: Healy's own experience with a job offer being rescinded at the University of Toronto, which had received a large donation from a drug company (Eli Lilly), is a prominent case he uses to illustrate how industry funding can infringe upon academic freedom and stifle critical research. "Disease Mongering": Healy argues that the pharmaceutical industry often engages in "disease mongering," marketing conditions to the public and physicians to create a market for their products rather than simply addressing genuine medical needs.  So that hopefully gives you some idea of the scope of his work, and his vision of transparency and integrity in the reporting one the effectiveness and risks of psychotropic medications. In our conversation today, he emphasized the importance of listening to patients who describe side effects of medications, such as SSRIs, in described the efforts of Big Pharma to suppress such complaints, giving psychiatrists "talking points" to reassure and quiet concerned patients. In general, a main focus of his career has been to challenge and confront the efforts of drug companies to suppress negative information about their products and troublesome and dangerous side effects. He said that one of the rationales the drug companies use is to say that disseminating that type of information will discourage many potential patients from using their products, and therefore miss out on the potential benefits of the medications. In fact, they have a name for this, "treatment hesitancy," and discourage open discussion of negative effects for this reason. I asked Dr. Healy if he's experienced direct negative pushback from drug companies, and he gave a surprising answer—he said no, that the major pushback he's gotten has actually been from colleagues—psychiatrists who have bought the party line disseminated by the drug manufactures. For example, when he gave his famous talk at the University of Toronto on the increase in suicidal urges associated with SSRI antidepressants, a famous psychopharmacologist, Dr. Charlie Nemeroff, got him fired. Here's the story on Dr. Nemeroff, According to AI: In the late 2000s, Nemeroff faced investigations and sanctions from Emory University for failing to disclose significant speaking and consulting fees from pharmaceutical companies like GlaxoSmithKline, raising questions about research integrity and conflicts of interest, notes The BMJ and The New York Times.  Although the antidepressant effects of SSRIs are controversial and hotly debated, their effects on the nervous system are not. Dr. Healy's research indicates that they have a suppression effect on the nervous system, which dulls the senses, and this can happen within 1 to 2 days. One of the more troublesome of these effects is called "genital numbing," which affects 9 out of 10  people talking SSRIs. This can result in difficulties with sexual arousal and greatly delayed orgasm, and apparently these effects can persist long after drug discontinuation. He said that these sensory effects can develop quickly, within a day or two of starting the medications. Even more chilling, he said that the problem can actually get worse when you discontinue the medication, and can sometimes persist for life. In addition, quite a few individuals have "bad trips" on SSRIs, although a minority clearly have "good trips." He said the best thing to do for a bad trip is to take the patient off of the medication immediately—and NOT increase the dose. He confirmed my impression that a common error with all antidepressants is to increase the dose—which simply increases the side effects. In addition to the genital numbing described above, he said the SSRIs cause "emotional numbing," which means a decreased capacity for joy as well as sorrow. One of the main activities in David Healy's life has been listening to patients, rather than discounting their complaints when they describe negative effects of medications. When asked about what alternatives to drugs he might recommend to someone struggling with depression, he said that sometimes, just doing nothing will be helpful, since most mood problems clear up spontaneously in 12 to 14 weeks. He said that most are simply human problems, not "mental disorders," but real-life problems, like relationship conflicts or social issues. Although we did not discuss it extensively on the show, I would point out that skillful, drug-free therapy with TEAM CBT can sometimes help as well, and that recent research has confirmed rapid often dramatic mood improvements with individuals using the Feeling Great app, which has been entirely free to anyone since the summer of 2025.  Finally, we do not advise anyone to discontinue or modify the dosages of any medications you have been prescribed without consultation with your doctor. The information in the Feeling Good podcast is of a strictly educational nature, and is not intended as treatment or medical advice. We thank you for listening to today's shocking but incredibly important dialogue with one of the pioneers and champions of greater ethical integrity and transparency in the psychiatric profession. It is sad, indeed, that we don't have more visionary critical thinkers like Dr. David Healy! David (H), Rhonda, and David (B)

In this episode of The Restored Minds Show, licensed therapist Matt Codde, LCSW shares some thoughts on medication and anxiety, including the role of SSRIs, benzodiazepines, placebo research, and how medication fits into a broader recovery journey.If you're struggling with anxiety, OCD, panic attacks, or other fear-based symptoms, you've probably wondered whether medication is the answer. In this episode, Matt explores the research, discusses common experiences people report with anxiety medication, and explains why medication may help some people — while not addressing the deeper cause of anxiety.Rather than taking an extreme position for or against medication, this conversation explores how medication might fit into a balanced recovery approach focused on emotional healing, exposure work, and long-term integration.

Jay Gunkelman and Dr. Mari Swingle are back to break down one of the most misunderstood drug classes in mental health — benzodiazepines. Jay walks through the real clinical picture of Klonopin and other benzos: dependence in as little as four weeks, life-threatening withdrawal, and how the brain simply can't learn while you're on them.The panel also covers SSRIs vs. benzos for anxiety, how EEG can literally catch a patient in a lie about drug use, MEG neurofeedback for pain management via the insula, and where neuroimaging technology is headed.

We press into why chronic disease grows as technology advances and how misaligned incentives in food, insurance, and medicine keep people sick. Jeff Hays shares what MAHA Uncensored uncovers, from SSRIs and PBMs to school lunch reform and simple habits that rebuild real health.• profit incentives driving sick-care over health• PBMs and insurance shaping drug prices• processed food, seed oils, and addiction tactics• how the Flexner Report reshaped medicine• media narratives and censorship pressures• SSRIs for kids, tapering, and side effects• terrain-focused strategies for cancer and diabetes• simple habits that beat most biohacks• policy levers for school meals and standards• where to watch MAHA Uncensored free“Go to mahamovie.com to watch the series free. Share it with someone you love.”Support the showElsa's AMAZON STORE Elsa's FAITH & FREEDOM MERCH STORE Elsa's BOOKSElsa Kurt: You may know her for her uncanny, viral Kamala Harris impressions & conservative comedy skits, but she's also a lifelong Patriot & longtime Police Wife. She has channeled her fierce love and passion for God, family, country, and those who serve as the creator, Executive Producer & Host of the Elsa Kurt Show with Clay Novak. Her show discusses today's topics & news from a middle class/blue collar family & conservative perspective. The vocal LEOW's career began as a multi-genre author who has penned over 25 books, including twelve contemporary women's novels. Clay Novak: Clay Novak was commissioned in 1995 as a Second Lieutenant of Infantry and served as an officer for twenty four years in Mechanized Infantry, Airborne Infantry, and Cavalry units . He retired as a Lieutenant Colonel in 2019. Clay is a graduate of the U.S. Army Ranger School and is a Master Rated Parachutist, serving for more th...

If you're on antidepressants and your sex drive has completely disappeared, I want you to know that you're not broken, and you don't have to choose between feeling mentally well and having a fulfilling sex life. SSRIs like Lexapro, Zoloft, and Prozac are genuinely life-changing for so many people, but nobody warns you that they can tank your desire, make orgasms nearly impossible, and quietly wreck your relationship in the process. In this episode, I'm breaking down exactly why this happens, and more importantly, what you can actually do about it. From simple timing hacks to alternative treatments that are showing real promise. In this episode, you'll learn: • Why SSRIs suppress desire and arousal on a hormonal level — and the one hack that can reduce side effects as soon as tonight • How to rebuild your sex drive when both you and your partner are medicated (yes, this is more common than you think) • The alternative treatments — TMS therapy, ketamine, and psilocybin — that are helping people get off antidepressants entirely More Dr. Emily:  • Shop With Emily! Explore Emily's favorite toys, pleasure accessories, bedroom essentials, and more — designed to support your pleasure and confidence. Free shipping on orders $99+ (some exclusions apply). • Join the SmartSX Membership: Access exclusive sex coaching, live expert sessions, community building, and tools to enhance your pleasure and relationships with Dr. Emily Morse. • Interested in 1:1 Coaching with Emily? Go to sexwithemily.com/coaching to apply!  • Sex With Emily Guides: Explore pleasure, deepen connections, and enhance intimacy using these Sex With Emily downloadable guides. • The only sex book you'll ever need: Smart Sex: How to Boost Your Sex IQ and Own Your Pleasure • Want more? Visit the Sex With Emily Website • Let's get social: Instagram | X | Facebook | TikTok | Threads | YouTube • Let's text: Sign up here • Want me to slide into your email inbox? Sign Up Here for sex tips on the regular. Chapters: 0:00 - Intro 0:31 - Sarah's Story: The SSRI Sex Drive Dilemma 3:50 - Why SSRIs Kill Your Libido (The Science) 6:50 - How Common Is This? Depression & Sex Stats 14:00 - Side Effects Breakdown: Vulva vs. Penis Owners 15:50 - Practical Hacks: Timing, Alcohol & Cannabis 20:53 - Alternative Treatments: TMS, Ketamine & Psychedelics 25:31 - Both Partners on SSRIs? How to Rebuild Intimacy 31:58 - The 36 Questions Study That Reignites Closeness 33:37 - Perimenopause, Hormones & Anti-Depressants at 48 Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Deb Muth 0:00 Welcome back to Let’s Talk Wellness Now. I’m your host, Dr. Zab, and we are continuing our discussion this week on 0:08 peptides. And so, if you haven’t heard our first conversation about peptides, 0:13 please go back and look at that episode. We talk all about the manufacturing, the safety, the quality of peptides, and we 0:20 dove into GLP1s. And today we’re going to dive into peptides for sexual 0:26 wellness, immune function, growth hormone, and all the amazing fun things 0:32 we can do with peptides. So, as usual, grab your cup of coffee or tea, settle 0:37 in, and let’s talk wellness now. And we’re going to take a short pause from our sponsor. I know we’ve got to do 0:44 that, you guys. They’re who keep us on the air. So, I’m going to pause for just a minute and be right back after this 0:50 message from our sponsor. Ladies, it’s time to reignite your vitality. Primal 0:56 Queen supplements are clean, powerful formulas made for women like you who want balance, strength, and energy that 1:03 lasts. Get 25% off at primal queen.com. Serenity Health. That’s primalqueen.com. 1:10 Serenity Health. Because every queen deserves to feel in her prime. All 1:15 right, everybody. We are back. And are you ready? We are talking all things peptide and I am opening the show today 1:23 with sexual wellness. Yes, I’m going there, you guys. I am going there. You 1:29 know, this has really become a big issue for people um of all ages. It’s not just 1:3 4us older people. It’s younger people, too. And there’s a whole variety of reasons why we have sexual dysfunction. 1:42 And when we’re talking about sexual dysfunction, we’re not just talking about it doesn’t work, right? Or I can’t 1:48 reach orgasm. A lot of it is around desire and um the thought of it and 1:54 wanting to connect, wanting to be kinder to one another, wanting to be touching 2:00 one another. A lot of it resolves or revolves around that. And so there are some peptides that can help us and I’m 2:08 really excited to be able to talk about those today. So the first one is called PT-141. 2:14 This targets the brain not the periphery. Right? So for many women I 2:20 will always tell you sex starts between here. It is a brain thing for us. It is 2:26 not necessarily a physical thing. For guys that’s a little different. It’s very physical. For women it’s all in our 2:32 brain. So tip for you men that are listening. You have to prime your woman’s brain first if you want her to 2:38 have sex with you that night. You have to be nice to her. You have to bring her flowers. Do the dishes for her. Do 2:45 something kind. Bring her a cup of coffee or tea or a glass of wine. Take her to dinner. You have to woo her. And 2:51 I don’t care how long you’ve been married. That has to happen. And tip number two, don’t say anything stupid 2:57 that day. I’m just being honest. When you guys say things that make us upset, 3:03 that lingers with us for the rest of the day. And it’s it’s a turnoff for us. And 3:08 for a lot of women, we can’t get past that when it comes time to snuggle at night. And sex doesn’t always have to be 3:14 at night either. So, you can tell I really love talking about this conversation, but we’re going to get into the peptide part of it because this 3:21 is going to help people. So, um, PT-141 is marketed as I’m going to slaughter 3:28 this name, Vali, and it represents a fundamentally different approach to 3:34 sexual dysfunction than the PDE5s inhibitors like Slenden, Viagra, 3:40 Tedataphil, which is Seialis. And while the PDE5 inhibitors work specifically by 3:47 enhancing blood flow to the genital tissues, PT-141 works centrally in the brain by 3:54 modulating neural s neural circuits involved in the sexual desire and 4:00 arousal. Now PT-41 is a cyclic hpatipeptide. It’s seven amino acid 4:07 peptide arranged in a cyclic structure that acts as a melanoortin receptor 4:13 agonist and with particularly the infinity for MC3R and MC4R subtypes. 4:20 It’s actually a metabolite of the melanotan 2, a peptide originally 4:26 developed for tanning that was also found to enhance sexual desire in early 4:31 studies. Now the melanoortin system in the brain is involved in multiple functions including energy homeostasis 4:39 but it also is involved in sexual motivation and arousal behaviors. The FDA approved PT-141 in 2019 specifically 4:48 for the treatment of acquired generalized hypoactive sexual desire 4:54 HSDD in permenopausal women. So for the first time we have a medication that was 5:01 approved by the FDA to use for women for sexual dysfunction. We have had all of 5:07 these seialis tedataphil viagros for men but we had nothing for women. And so 5:12 this is amazing that this is available for women and approved by the FDA. It’s a big deal. This represents the first 5:19 and only FDA approved medication specifically targeting these circuits of sexual desire rather than the peripheral 5:27 arousal mechanisms. And this indication is quite specific, meaning it was developed at some point, not lifelong. 5:35 So I if you’ve had sexual dysfunction your entire life, this medication was 5:40 not approved for you. But if it’s something that you developed over time, like when you went through pmenopause or 5:46 menopause or some women have this experience happen after childirth, that’s what we’re talking about here. 5:53 Now, it’s also not just um supposed to be used if you dislike your partner, 5:59 right? If your relationship is bad and you dislike your partner, this probably isn’t going to fix a ton. It might help 6:05 a little bit, but that’s not what it’s meant for. So, you really have to know what you’re using it for and why. And 6:11 the other thing that I would say is this is something that we don’t go to if your hormones are not balanced properly. You 6:17 have to balance your hormones properly before using something like this because it still may not work. Now, the only 6:24 caveat to that is if you’re a woman that has a risk of breast cancer and can’t use hormones, then that’s a different 6:31 story and we would have that conversation about whether or not this medication would be appropriate for you. Now, the FDA label specifies PTA1 uh 6:39 PT-141 as it not being indicated for HSDD in causes where low sexual desire 6:46 is due to coexisting medical or psychiatric conditions, problems with relationships, like we had talked about, 6:53 side effects to medications or other substance use. This specifically reflects the importance of differential 6:59 diagnosis. Low sexual desire can have many root causes and PT-41 is only 7:05 appropriate when those causes have been ruled out. Now, I have I used PT41 in 7:10 people who have sexual dysfunction issues as a result of using 7:16 anti-depressants. Yes, I have. I’ve used Flynn in that effect as well. And it 7:21 does work sometimes, but it doesn’t work completely. But you need to know that that is not what the approval is for the 7:27 FDA. So that is done in something that we call off label use. So very important 7:33 to know. Now in these clinical trials leading to FDA approval, this was published by Kinsburg and colleagues in 7:40 obstetrics and gyne gynecology in 2019. PT-141 demonstrated statistically 7:46 significant improvements in sexual desire and decreases in distress related 7:51 to low desire compared to placebo. The effects manifest over 45 minutes to 7:56 several hours after the injection and the mechanisms involved modulation of dopamine and melanoorton pathways in the 8:04 hypothalamus and the brain regions that involved sexual motivation. Now cardiovascular effects of PT 141 require 8:12 careful attention. This drug causes transient increases in blood pressure about 3 to four points and transient 8:20 decreases in heart rate. And because of this, it is contraindicated in patients 8:25 with uncontrolled hypertension or known cardiovascular disease. And it has been studied in patients who’ve had recent 8:32 cardiovascular events or sorry hasn’t been studied hasn’t been studied in patients who’ve had recent 8:39 cardiovascular events. So patients need to have their blood pressures checked before starting therapy. Nausea is 8:45 extremely common. It is one of the biggest things I often will tell people to take an anti-nausea medicine if 8:52 they’re going to do this because the last thing you want to do is inject this medication and think it’s going to give 8:57 you this great time with your partner and you’re so nauseated that you can’t even perform, don’t want to kiss, don’t 9:05 want to do anything. It it can be pretty profound for some people. um it does affect about 40% of the patients in 9:12 clinical trials which is why many clinicians require or recommend an 9:17 anti-nausea medication like I had just said other common adverse effects include flushing injection site 9:24 reactions headache in about 13% of the population which I have seen worse if 9:30 people are prone to headaches and the headaches are pretty intense so I will also have them premedicate if they have 9:36 that um sensitivity ity with a Tylenol or Advil, Alie, whatever it is they 9:42 typically use for their headaches to help prevent that from occurring. Now, some patients also experience a 9:50 generalized hyperpigmentation of their skin, particularly in areas with chronic friction, and this may not be reversible 9:57 after discontinuation. So from an integrative perspective, PT-41 10:03 represents one tool in addressing female sexual dysfunction, but it should never be the first or only intervention. And 10:11 low sexual desire in women is complex. Multiffactorial involving hormonal imbalances, low testosterone, estrogen 10:18 deficiency, progesterone imbalances, thyroid dysfunction, adrenal dysfunction, and with elevated or 10:24 disregulated cortisol levels, sleep deprivation, relationship issues, unresolved trauma, including sexual 10:31 trauma, chronic pain, body image concerns, and medication side effects such as SSRIs are notorious for this. So 10:39 a comprehensive hormone panel including total and free testosterones, estradile, 10:45 progesterone, DHEA, thyroid function in cortisol assessment, ideally four-point 10:51 cortisol, salivary should precede any pharmacological intervention. And additionally, addressing the 10:57 psychological component and relationship dimensions through appropriate therapy is necessary. I have a lot of patients 11:03 that say, “This is just too much work for sex. I don’t want the side effects. I don’t want to deal with this.” and that’s totally fine. But for some 11:09 people, their sexual dysfunction is actually causing more problems on their 11:14 relationship and they want to do something to fix that. And just know that if you’re using a peptide like this 11:20 that comes with some of these side effects and you have to premedicate for it, it is not the end of the world. Um, 11:27 but it may be a possibility that you may need that. So, let’s dive into body composition and growth hormone access. 11:34 So Tesmarellin is the only FDA approved GH 11:40 analog. Tesarelin is marketed as Agrifta and Agria SV. It is a synthetic analog 11:48 of human growth hormone releasing hormone. So GH RH human growth hormone 11:53 releasing hormone. These things are such long names it’s confusing and it’s difficult to spit out, right? It 11:59 consists of 44 amino acids. The structure is identical to our own 12:05 body’s growth hormone GHR um with the addition of trans3 hexonol group which 12:14 stabilizes the molecule that extends its half-life compared to the native GHR. 12:19 The mechanism of tesmarellin is elegant in its preservation of physiological 12:24 growth hormone GH secretion patterns and rather than administering an exogenous 12:30 growth hormone directly, tesmarillin binds to the GH receptor in the anterior 12:36 pituitary gland stimulating the indogenous pulsatile release of GH. So 12:42 you know it it’s slower in that stimulation and it pulsates instead of a direct rise and fall. This pusile 12:49 pattern more closely mimics natural GH secretion which occurs in bursts 12:54 primarily during sleep. The GH then stimulates the liver to produce insulin-like growth factor IGF-1 which 13:01 exerts many of the downstream metabolic effects including lipolytic effects on 13:07 the atapost tissue. So fat atapose and how we break that down. The FDA approved 13:13 tesmarellin in 2010 for a very specific narrow indication, the reduction of 13:19 excess abdominal fat in HIV infected patients with lipodistrophe. This 13:25 condition characterized by abnormal fat redistribution with accumulation of visceral body fat and the loss of 13:32 subcutaneous fat in face and limbs developed as a complication of an 13:37 antiviral therapy particularly with older protease inhibitor reg uh 13:42 regimens. The visceral fat accumulation in patients is not just cosmetic. It’s associated with increased cardiovascular 13:49 risk, insulin resistance, and inflammatory markers. The pivotal trial that led to the FDA approval included 13:56 work by Stanley and colleagues published in the annuals of internal medicine in 2014. It demonstrated that tesmarillan 14:03 significantly reduced the visceral atapose measured by CT scan by approximately 15 to 20% which is a 14:10 significant difference to placebo over a short period of time only 26 weeks. Now, 14:16 interestingly, the total body uh weight typically remained stable or even 14:21 increased slightly as the reduction of visceral fat was sometimes offset by increases in lean body mass or 14:28 subcutaneous fat. This highlights an important point. Tesmearellin is not a weight loss drug in its conventional 14:34 sense. Its effects are specifically on body composition and fat redistribution. 14:40 Now the glucose metabolism effects of tesmarellin do require careful monitoring because GH and IGF1 can 14:47 induce insulin resistance. Tesmearellin can increase glucose levels and hemoglobin A1C and in these clinical 14:54 trials glucose tolerance and new onset diabetes occurred in some patients. So 14:59 this creates a therapeutic paradox while res reducing visceral fat we should theoretically improve metabolic health. 15:07 The GH mediated insulin resistance can worsen the glycemic control and patients 15:12 with diabetes require particularly close monitoring. The potential need for adjustment in diabetic medications can 15:19 occur. So I already know what you guys are thinking. Can I use Tesmarellin and 15:24 GLP1 at the same time? And the answer is yes. Especially in those people that we 15:30 know have an insulin resistance already or are prone to that, we can use lowd 15:36 dose micro doing GLP-1 along with tesmarellin to help prevent this from 15:42 occurring um or reduce the risk of it occurring. Now there are some other adverse related problems to growth 15:49 hormone access which include fluid retention which can uh manifest as uh 15:55 ankle swelling, joint pain, muscle pain, paristhesas, carpal tunnel syndrome is 16:01 common to see. Of course you can always see injection site reactions reported about 26 to 30% of the time in the trial 16:08 participants. And this also theoretically has a concern about IGF-1 elevation potentially promoting 16:14 malignancy through long-term data is limited. So we have to be cautious about 16:20 this but it is a growth hormone and anything that is a growth hormone can cause cells to grow and it cannot 16:26 necessarily differentiate between healthy cells and bad cells. So the drug is contraindicated is contraindicated in 16:33 patients with active cancer and in patients with the disruption of the HPA access from conditions like pituitary 16:40 tumors, pituitary surgery, head of radiation um and traumatic brain injury. 16:46 Now off label use of tesmarellin for general anti-aging or body composition 16:51 optimization in non-HIV population, it doesn’t have FDA approval. There is no 16:58 FDA studies. um that promote this, but practitioners do prescribe it for these 17:04 purposes under an experimental and not supported by FDA approved indications. 17:10 And um from an integrative medical standpoint, optimizing natural growth 17:15 hormone secretion through lifestyle interventions, high quality sleep is important. GH primarily is excreted 17:22 during sleep and deep sleep waves. So improving your deep sleep is important. Intermittent fasting can also increase 17:28 growth hormone by five-fold as demonstrated in a Hartman and colleagues uh study from the journal of clinical 17:35 endocrinology and metabolism in 1992. And highintensity interval training, adequate dietary protein, blood sugar 17:42 control, these all can help naturally increase your growth hormone. So, let’s 17:47 dive in now and talk about bone health. peptide hormones um such as oh I’m gonna 17:54 I’m gonna really slaughter this name. Terraparatide is a true bonebuilding 18:01 peptide. It’s marketed as forio. It’s a recumbent form of the first 34 amino 18:08 acids out of 85 of the human parathyroid hormone PTH. It represents a unique 18:13 approach to osteoporosis treatment because it’s one of the few truly anabolic anabolic bone therapies meaning 18:21 it actively binds new bone rather than simply preventing bone loss. The biology 18:26 of parathyroid is fascinating and seemly contraindicated or uh contradictory. 18:32 Continuously sustained elevations of PTH as occurs in hyperarathyroidism 18:37 is catabolic to bone. So people who have hyperarothyroidism typically have significant bone loss 18:44 especially before it’s diagnosed and it causes causes increased bone 18:49 reabsorption loss of bone density increased fracture risk and however 18:55 intermittent exposure to PTH as achieved with once daily uh injections of forio 19:01 has the opposite effect. This intermittent exposure preferentially stimulates osteoblasts bone building 19:08 cells over osteoclasts bone reabsorbing cells and it leads to 19:13 the net bone formation. So terraparatide binds to the PTH receptors on 19:20 osteoblasts and renal tubular cells in bone. It increases the number of 19:25 activity of osteoblasts stimulating the differentiation of osteoblast precursor cells and may 19:32 reduce osteoblast apoptosis basically programmed cell death allowing this bone 19:37 building cell to work longer. The result is increased bone formation, improved bone architecture and tbacular 19:45 connectivity and ultimately increased bone mineral density um particularly in the hip and the spine which is so 19:51 difficult to regain. The FDA approved this medication in 2002 based on pivotal 19:57 studies by Near and colleagues published in the New England Journal of Medicine in 2001 which demonstrated significant 20:05 reductions in vertebral and non-vebral fractures in post-menopausal women with 20:11 osteoporosis. specifically uh reduced new vertebral fractures by 20:17 65% and nonvettebral fragility fractures by 53% 20:23 compared to placebo over a median followup of 21 months. This is really 20:29 incredible because we have not seen this kind of um change uh in other 20:35 medications that we’ve used for osteoporosis. So current FDA approval 20:40 indicates uh this for post-menopausal women with osteoporosis at high risk for 20:46 fracture, men with primary or hypoconatal osteoporosis at high risk for fracture 20:53 and men and women with glucocord cord glucocordide 21:00 induced osteoporosis at high risk for fracture. The high risk qualifier is 21:05 important. uh terrapeptide is reserved for patients with severe osteoporosis, 21:11 multiple fractures, very low low bone density and those who have failed or are 21:16 intolerant of other therapies. The most significant concern for this medication 21:21 is highlighted in a boxed warning with rat toxicology studies where it caused 21:27 osteioaroma which is a bone cancer in a dose dependent and treatment duration dependent manner. The revolence of this 21:34 finding to humans is debated. Rats have fundamentally different bone biology than humans with continuous bone growth 21:41 throughout life and different PTH receptors. Now post marketing 21:46 surveillance in humans hasn’t shown a clear increase in osteocaroma risk but 21:51 theoretically concerns persist and because of this terapeptide is 21:57 contraindicated in patients at risk baseline risk for osteioaroma 22:02 including those with pageantss disease of the bone unexplained elevations of alkaline phosphate prior skeletal 22:10 radiations bone metastases or skeletal malignancies and pediatric patients or young adults 22:16 with open hyes. There’s also a lifetime treatment duration of only 2 years and 22:22 terrapeptide can cause transient hypercalcemia. So an elevated blood calcium and as PTH normally increases 22:31 calcium levels by enhancing bone reabsorption, increasing renal calcium 22:36 reabsorption and promoting activation of vitamin D which increases intestinal calcium absorption. Some patients 22:43 experience orthostatic hypotension within 4 hours of injecting requiring 22:48 caution in at risk populations for blood pressure. Common side effects include 22:53 muscle pain, joint pain, pain in the limbs, nausea, headache, and dizziness. So from an integrative bone health 23:00 perspective, terrapeptides should be part of a comprehensive strategy. Adequate calcium intake, 500 to a,000 23:08 milligrams of calcium a day from food and supplements combined. and vitamin D. 23:13 Getting vitamin D levels of at least 50 to 80 are essential for the drug to work 23:20 optimally. But beyond this, bone health requires vitamin K2, which directs calcium into the bones rather than soft 23:27 tissues, magnesium as a co-actor in bone metabolism, trace minerals like boron, 23:33 copper, silica, and of course, adequate protein intake, which many of us, especially as women, don’t do 0.8 8 to 1 23:42 gram of protein per kilogram of body weight, weightbearing exercise. Of 23:47 course, these all provide mechanical signals that complement the biochemical 23:52 symbol uh signals of terrapeptide. Sequential therapy is also critical. The 23:58 bone mass gains from terraparatide can be lost if patients don’t transition to 24:05 an anti-resorbbitive agent a bisphosphinate after completing this therapy and the anabolic effects to 24:12 build bone but maintaining the new bone requires preventing excess reabsorption. 24:18 So positive things about this but there are definitely some concerns as well. So 24:23 the next one we’re going to talk about is Lu Prolrooide. It is marketed under 24:29 the multiple brand names of Lupron, Depo, Eligard, and it’s a synthetic 24:34 nonapeptide analog of naturally occurring ginonadotropen releasing 24:39 hormone G&R, also called luteinizing hormone releasing hormone, LHR. 24:46 It’s a fascinating example of how manipulating natural hormonal feedback systems can create therapeutic effects. 24:53 So, G&RH is normally secreted in a pulsatile fashion by the hypothalamus 24:59 and travels to the anterior pituitary where it binds to G&R receptors and 25:05 stimulates the release of luteinizing hormone LH and follical stimulating hormone FSH. These ginatotropins signal 25:13 the ovaries or the testes to produce sex hormones, estrogen, progesterone in 25:18 women, testosterone in men. Uh, luoprololi lupron as a GNR agonist 25:26 initially mimics the action of natural G&R causing an acute flare response with 25:33 uh increased LHFSH secretion which temporarily increases sex hormone 25:38 production. However, the continuous administration which is in the depo 25:44 formulations, the GNR receptors in the pituitary become desensitized and 25:50 downregulated. And after about 2 to four weeks of continuous exposure, LH and FSH 25:56 secretion is profoundly suppressed, leading to what’s termed as chemical 26:01 castration. Testosterone levels in men drop to castrated levels less than 50 26:08 and estrogen production is marketkedly suppressed in women. This bifphasic 26:13 response creates both therapeutic applications and management challenges in prostate cancer where tumor growth is 26:20 typically androgen dependent and the ultimate goal is testosterone suppression. However, the initial 26:27 testosterone surge during the flare phase can temporarily worsen symptoms potentially causing increased bone pain, 26:34 urinary obstruction, or even spinal cord compression in patients with metastatic 26:40 disease. This is why uh luoprolide is often started with an anti-ad androgen 26:47 like bicladamide for the first two to four weeks to block the effects of the 26:52 testosterone surge. The FDA has approved lupalide for multiple indications across 26:59 formulations. In oncology, it’s used for palletive treatment of advanced prostate cancers. In gynecology, various 27:06 formulations are approved for endometriosis, for pain management and lesion reduction and for fibroids. 27:13 Typically for pre-operative uh hematological improvement in anemic patients. In pediatrics, it’s used for 27:20 central precocious p puberty basically to halt the premature sexual development of these young people. Now, there are 27:28 adex uh adverse effect profile that reflects profound hormonal suppression. 27:34 In men treated for prostate cancer, hot flashes affect about 59% of the patients. Other common effects include 27:41 general pain, swelling, bone pain. Um long-term use of these medications leads 27:47 to metabolic changes. It increases fat mass. It decreases lean mass. It worsens 27:53 insulin sensitivity, disrupts the cholesterol uh lipid panels, increases 27:59 diabetic risk, has some concerns over cardiovascular disease. And the metaanalysis have shown increased risks 28:06 of heart infarction, myocardial inffection, sudden cardiac death, and stroke in populations receiving 28:13 long-term androgen deprivation therapy. The bone effects are particularly dramatic. Without sex hormones, bone 28:20 density decreases significantly, typically 3 to 4% per year during the 28:26 first two to three years of therapy. And this bone loss may not fully be reversible after the the therapy 28:32 discontinues. The American Society of Clinical Oncology recommends bone density monitoring and consideration of 28:39 bisphosphinates uh in men receiving long-term androgen deprivation. In women treated for 28:46 endometriosis or fibroids, the estrogen suppression creates a hypoestrogenetic state similar 28:54 to menopause. Hot flashes affect 90% of patients with other common effects 29:00 including headaches, emotional irritability, decreased sex drive, vaginal dryness, bone density loss. And 29:08 because of these bone concerns and treatment duration with endometriosis, typically limited to six months, though 29:14 some formulations allow for longer use with adback hormonal therapy to 29:20 partially mitigate these side effects. The mood and cognitive effects can be s 29:25 significant. I’ve seen it over the years. the depression, the memory impairment, difficulty focusing and 29:31 concentrating. It can be very very traumatic and the quality of life that 29:37 happens for these uh women and men can be unbearing for many of them. Um, from 29:44 an integrative perspective, patients receiving this medication need comprehensive support care. Bone health 29:51 interventions using calcium, vitamin D, vitamin K2, weightbearing exercise, 29:58 cardiovascular risk management becomes critical, including blood pressure monitoring, lipid management, diabetes 30:05 screening. For hot flashes management, some patients respond to black coohos, 30:10 sage, or vitamin E. Though evidence is mixed and individual response varies, 30:16 omega-3s may help with the mood and the inflammation, resistance training becomes specifically important to 30:22 preserve lean muscle mass in the face of hormonal suppression. 30:27 Now there’s something called calcetonin salamon which is marketed as miaelin. 30:34 It is a nasal spray. It is now discontinued. And foral is the new 30:39 synthetic polyeptide hormone of 32 amino acids identical to calcetonin of salamon 30:47 origin. It represents an interesting case study in how initial promise gives 30:52 way to safety concerns that regulate a therapy to historical footnote status. 30:58 Calcetonin is naturally occurring hormone in humans. It’s secreted by the paraphalicular sea cells in the thyroid 31:04 gland. Its primary physiological role is to lower blood calcium levels by 31:10 directly inhibiting osteoclast activity, reducing bone reabsorption, increasing 31:16 renal calcium secretion or excretion, and possibly reducing the intestinal 31:21 calcium absorption. So, salamon calcetonin is used therapeutically because it’s more potent and longer 31:27 acting than human calcetonin. The FDA initially approved calceton and salmon 31:34 for several indications post-menopausal osteoporosis in women more than five 31:39 years post-menopausal when alternative treatments are not sustainable. Padet’s 31:44 disease for bone and hypercalcemium as emergency treatments. The nasal spray formulation is particularly popular for 31:53 osteoporosis because it offered a non-injectable alternative to bisphosphinates. 31:58 However, in 2012, the European Medicine’s Agency, EMA, conducted a 32:05 comprehensive safety safety review after a poolled analysis of 21 clinical trials 32:10 involving over 10,000 patients showed a statistically significant increase in 32:15 malignancy risk in patients treated with calceton salamon compared to compared to 32:21 placebo. The overall malignancy rate was 4.1% in calcetonin treated patients 32:28 versus 2.9% in placebo patients. The types of cancer 32:34 varied with no single cancer type predominating, making it difficult to establish a clear mechanistic link. 32:41 However, the signal was concerning enough that the EMA restricted the use of calcetonin containing medicines. In 32:48 the United States, the FDA issued communications about malignancy signal and conducted its own review. While they 32:56 didn’t fully withdraw the drug, the cons consensus shifted dramatically. The nasal spray formulations miaelson was 33:03 voluntarily discontinued by the manufacturer and current clinical practice guidelines now consider 33:10 calcetonin salamon as a second line or lower option for osteoporosis. While 33:15 behind bisphosphinates, dennism mob, uh, terrapeptide, the analesic effect of 33:21 calcetonin in bone pain, particularly in acute vitibbral, uh, compression 33:26 fractions from osteoporosis or pageantss disease may still provide a role for short-term use in these selected 33:32 patients. The mechanism of this pain relief is unclear, but may involve 33:38 effects of endorphin systems and/or direct actions on pathways. The history serves as an important reminder in 33:45 peptide medicine. Initial approval and early clinical use does not guarantee 33:50 long-term safety effects. Post marketing surveillance and poolled analysis of the clinical trial data can reveal adverse 33:58 effects that weren’t apparent in initial studies. It also underscores why newer 34:04 agents with better safety profiles um have largely replaced calcetonin in 34:10 clinical practice. So this is really an important thing. Not one thing stays the same forever. We have to change as we 34:18 identify new and better products as we identify problems and concerns. I will 34:24 always tell my patients if you are uncertain of taking a new drug which we 34:30 all should be wait five years. Within five years we are going to find the 34:36 problems that they didn’t find in the clinical studies. Remember, a lot of these clinical studies are small, small 34:43 groups, short periods of time. It’s expensive to do these trials. So, if you 34:49 wait for five years, in the first two to three years, you will see the problem start to emerge. And what are you going 34:55 to look for? You’re going to look for the the news um commercials from lawyers 35:02 suing a drug. And they will tell you what the problem is. and then you can decide, is this something that I want to 35:09 use or not. Don’t jump on bandwagon and be the first one to do this, especially 35:14 if you’re sensitive. You know, give it time so you can see exactly what’s going on. So, I’m going to end our show on 35:22 this and we are going to pick up on part three of peptide therapy in our next 35:28 segment where we’re going to talk about the investigational peptides and some 35:34 exciting things that are happening with that. So, I want to thank you for joining me today on Let’s Talk Wellness 35:39 Now. It’s always a pleasure having a conversation with you guys and I hope this brings value to you with what we’re 35:45 talking about. If you have ideas for topics that you want me to discuss, 35:51 please message us, you can share your comments on Facebook, you can email us, 35:58 um you can get a hold of us however you would like to share that. I do look at the comments below in the episodes as 36:04 well. So you can place your comments there. And once again, one of the best things you can do for me is like, 36:11 subscribe, and share so that we can spread the messages of what we’re doing. 36:16 I do this at no cost. I don’t make any money out of this. I do this as an 36:21 educational purpose for everybody else. I love doing it, but it really helps us 36:28 on the algorithms if you would be just willing to like, subscribe, and share. 36:33 So, thank you for spending your time with me. I know time is important.The post Episode 257 – Peptides for Sexual Wellness & Hormonal Health: PT-141, Growth Hormones, Bone Health & More! first appeared on Let's Talk Wellness Now.

Send a textFeeling better shouldn't feel like a mystery. We dig into the real mechanics of antidepressants—how SSRIs, SNRIs, TCAs, MAOIs, and atypicals shift brain chemistry over time—and why the two-to-six week window makes sense once you see how stabilization actually works. Along the way, we unpack the biggest myths: no, these meds don't rewrite your personality, and no, they don't create the craving cycle you see with opioids or benzodiazepines. What they can do is give you a steadier emotional floor so therapy and daily habits finally stick.We also talk about why pairing medication with therapy changes the game. When your baseline moves from chaos to calm, you make clearer choices and build momentum. Hypnosis shows up here as a clinical tool, not a stage trick—useful for downshifting anxiety, reframing pain, and training attention so it stops feeding the spiral. Think of it as cognitive strength training: short, focused sessions that unlock better days while medication does its quieter work in the background.If you've ever asked, “Will I still be me?” try a sharper question: “When was I my best me?” Answering that helps shape treatment choices, from activating meds for low energy to options with fewer sexual side effects, and it gives therapy a specific target to build toward. We offer practical steps for the in-between weeks—mood tracking, micro-rituals, honest check-ins—and a reminder to taper with your prescriber if you're making changes. Stability isn't perfection; it's the space where joy, focus, and connection become possible again.If this conversation helps, share it with someone who's stuck in the fog. Subscribe for more grounded mental health guidance, leave a quick review to support the show, and tell us: what's one myth about antidepressants you want the world to drop?FIND ME:My Website: https://motorcityhypnotist.com/podcastMy social media links: Facebook: https://www.facebook.com/motorcityhypnotist/YouTube: https://www.youtube.com/channel/UCCjjLNcNvSYzfeX0uHqe3gATwitter: https://twitter.com/motorcityhypnoInstagram: motorcityhypnoFREE HYPNOSIS GUIDEhttps://detroithypnotist.convertri.com/podcast-free-hypnosis-guidePlease also subscribe to the show and leave a review.(Stay with me as later in the podcast, I'll be giving away a free gift to all listeners!)Change your thinking, change your life!Laugh hard, run fast, be kind. David R. Wright MA, LPC, CHTThe Motor City Hypnotist

Hot flashes. Brain fog. Sleepless nights. For too long, we've mislabeled midlife women's health as burnout, anxiety, or a loss of ambition. But what if the real issue isn't performance — it's hormones? In this episode of Hello Monday, Jessi Hempel talks with Joanna Strober, founder and CEO of Midi Health, about menopause, perimenopause, hormone therapy, and power at work. Together, they unpack how gaps in women's healthcare during midlife are quietly pushing talented leaders out of the workforce at the exact moment they should be accelerating. After struggling to get proper treatment for her own perimenopause symptoms, Joanna built Midi Health to deliver insurance-covered, expert virtual care focused on women in midlife. This conversation goes beyond hot flashes — it's about workplace equity, hormone replacement therapy (HRT), ageism, health misdiagnoses, and why normalizing menopause could unlock a generation of leadership. Because menopause isn't a road bump, with the right care, it can be a power surge. Jessi and Joanna discuss: The difference between perimenopause and menopause, and why the distinction matters for women's health at work Why 1 in 5 women in their 40s are prescribed SSRIs — and how hormonal shifts are often overlooked Hormone replacement therapy (HRT) and non-hormonal menopause treatments The workplace impact of untreated menopause symptoms, including research showing women may lose authority during visible symptoms like hot flashes How employers can support midlife women through better insurance coverage  Ageism in the workplace — and why women in their 50s may be primed for peak performance How normalizing menopause conversations can help women reclaim power Follow Joanna Strober and Jessi Hempel on LinkedIn. We will be launching the Hello Monday book club soon. If you're interested in joining, send us an email at hellomonday@linkedin.com and let us know!  Watch on YouTube: https://bit.ly/hellomonday-LI-video-youtube  Watch/Listen on Spotify: https://bit.ly/hellomonday-LI-video-spotify⁠ Listen on Apple: https://bit.ly/hellomonday-LI-video-apple⁠ 

Chaos didn't arrive all at once for Charissa; it accumulated.. custody hearings, restraining orders, police lights outside the window, until crisis felt like the only rhythm of home. We sit with her through the memories most people look away from: sibling fights recorded for proof, eighty-plus CPS reports that opened and closed like revolving doors, and a medical maze where stimulants and SSRIs masked trauma instead of meeting needs. What emerges is a rare, unflinching map of how systems miss children when they treat behavior without context and listen to adults more than the kids living the truth.Charissa explains how overmedication took her childhood offline, sleeping through classes, wired at night, and twice rushed from school with a 160 resting heart rate while suspicions of Munchausen by proxy pulsed beneath the surface. She draws careful lines between control disguised as care, fragmented providers, and a culture that treats children as parental property until eighteen. When an arrest at 18 forced independence, she found a way out: temporary housing, college, and a mission to make sure other young people don't get swallowed by the same gaps. Today, she's shaping policy, co-creating a national playbook of best practices, and pushing for adoption of the UN Convention on the Rights of the Child.Across the conversation, we unpack what “best interests of the child” should mean in practice: youth voice at the table for hearings and family meetings, transparent case communication, limits on polypharmacy, tracking doctor switching, and trauma-informed support that tackles root causes instead of staging a calmer scene. Teresa's ask is simple and radical: believe kids enough to investigate the inconvenient explanation. If we center respect, agency, and safety, we can transform CPS touchpoints from crisis management into real protection—and stop calling survival symptoms “the problem.”If this story moved you, subscribe to Multispective, shSend a text Support the showAdditionally, you can now also watch the full video version of your favourite episode here on YouTube. Please subscribe, like or drop a comment letting us know your thoughts on the episode and if you'd like more stories going forward!If you would like to offer any feedback on our show or get in touch with us, you can also contact us on the following platforms: Website: www.multispective.org Email: info@multispective.org Instagram: www.instagram.com/multispectivepodcast Facebook: www.facebook.com/multispectiveorg Reddit: www.reddit.com/r/multispective Support the show: https://www.patreon.com/multispectiveProducer & Host: Jennica SadhwaniEditing: Stephan MenzelMarketing: Lucas Phiri Fatty15 promotes healthy metabolism, balanced immunity, and heart health. 2 out of 3 customers report near-term benefits, including calmer mood, deeper sleep or less snacking, within 6 weeks. 20% off on purchases link and code: ...

Can something as simple as walking or running rival antidepressants? In this episode of The Lebanese Physicians Podcast, I sit down with Dr. Farid Talih, American board–certified psychiatrist, sleep medicine and addiction specialist, to explore the powerful science behind exercise as a treatment for depression and anxiety. We dive into: How exercise reshapes the brain through BDNF (brain-derived neurotrophic factor) Why movement works differently than SSRIs and psychotherapy The role of lactate, cortisol, endorphins, and the “runner's high” Exercise vs medication: when to use one, the other, or both Group exercise, loneliness, and mental health Practical, realistic ways to “prescribe” movement in real-world settings Cultural, socioeconomic, and access barriers to exercise Exercise in pregnancy, postpartum depression, aging, and addiction recovery Why mental health care must stay individualized, humane, and holistic This episode challenges the idea that mental health treatment is only about prescriptions and reminds us that movement, connection, and context matter.

Send a textA four-hour swim through rough seas sets the tone for resilience, and we channel that grit into a clear-eyed tour of antidepressants that actually help people get their lives back. We pick up our series on depression treatment with a practical, plain-English guide to SSRIs, SNRIs, TCAs, MAOIs, and atypicals—how each class works on serotonin, norepinephrine, or dopamine, what side effects to expect, and why some meds also ease nerve pain or insomnia. If you've ever wondered why results take two to six weeks, we break down the brain science: receptors need time to recalibrate and new pathways to form, which is why steady dosing and patience pay off.We share how we approach titration, when to hold, when to adjust, and how pharmacogenomic tools like Genesight can reduce trial-and-error by flagging side-effect risks up front. You'll hear why bupropion can boost energy and focus with fewer sexual side effects, when mirtazapine's sedation and appetite increase are a feature not a bug, and why TCAs and MAOIs still matter for tough, treatment-resistant cases. Most importantly, we explain why medication is a tool, not the destination: better outcomes come when meds lower symptom intensity and therapy builds lasting skills—sleep, exercise, reframing, and relationship repair.We also get candid about the real-world mess: insurance hurdles that delay payments and care, and how clinics navigate those roadblocks to keep patients supported. It's an unfiltered, compassionate look at what works, what to watch for, and how to advocate for the help you deserve. Press play to get smarter about your options, prepare for part three on myths and misconceptions, and take a step toward relief that lasts.If this helped, follow the show, share it with a friend who needs clarity, and leave a quick review to help more listeners find solid mental health guidance.FIND ME:My Website: https://motorcityhypnotist.com/podcastMy social media links: Facebook: https://www.facebook.com/motorcityhypnotist/YouTube: https://www.youtube.com/channel/UCCjjLNcNvSYzfeX0uHqe3gATwitter: https://twitter.com/motorcityhypnoInstagram: motorcityhypnoFREE HYPNOSIS GUIDEhttps://detroithypnotist.convertri.com/podcast-free-hypnosis-guidePlease also subscribe to the show and leave a review.(Stay with me as later in the podcast, I'll be giving away a free gift to all listeners!)Change your thinking, change your life!Laugh hard, run fast, be kind. David R. Wright MA, LPC, CHTThe Motor City Hypnotist

Send a textEver been told “antidepressants change your personality” or “you'll be on them forever”? We're cutting through the noise with a clear, grounded tour of how modern antidepressants work, why they were discovered by accident, and what real people should know before starting, switching, or stopping. We share the surprising roots of MAOIs and tricyclics, how SSRIs became mainstream, and where ECT fits today for treatment-resistant cases. No jargon, no scare tactics—just the essentials you can use to make smarter choices with your clinician.We break down brain basics in plain English: neurons, synapses, and the roles of serotonin, norepinephrine, and dopamine in mood and motivation. You'll hear why reuptake inhibition matters, what changes to expect first, and how to spot common side effects like sleep shifts, nausea, and sexual dysfunction. Just as important, we draw a bright line between dependence and addiction, and explain why tapering off—never quitting cold turkey—protects your body while you pivot your plan.Along the way, we talk stigma, ask the questions your provider hopes you'll bring, and explore how medication pairs with therapy, sleep, movement, and community to create lasting relief. Plus, a gripping “Winner of the Week” rescue, show updates from the Motor City Hypnotist studio, and a quick adoption spotlight for Minnie from Detroit Dog Rescue. If you've been curious, cautious, or confused about antidepressants, this conversation gives you the clarity to move forward with confidence.If this helped, follow the show, share it with a friend who needs straight answers, and leave a review so more listeners can find us. Got a question we didn't answer? Send it our way and we'll tackle it next.FIND ME:My Website: https://motorcityhypnotist.com/podcastMy social media links: Facebook: https://www.facebook.com/motorcityhypnotist/YouTube: https://www.youtube.com/channel/UCCjjLNcNvSYzfeX0uHqe3gATwitter: https://twitter.com/motorcityhypnoInstagram: motorcityhypnoFREE HYPNOSIS GUIDEhttps://detroithypnotist.convertri.com/podcast-free-hypnosis-guidePlease also subscribe to the show and leave a review.(Stay with me as later in the podcast, I'll be giving away a free gift to all listeners!)Change your thinking, change your life!Laugh hard, run fast, be kind. David R. Wright MA, LPC, CHTThe Motor City Hypnotist

Something dark is happening in America and almost no one is connecting the dots. From the rise of mass shootings to the explosion of antidepressant use, I break down what RFK Jr is uncovering about SSRIs, cultural confusion, and a spiritual fog settling over the West  . We also expose the media spin around trans violence, Europe's identity crisis, and why leaders like Marco Rubio are calling the West back to strength before it is too late.   Podcast Episode 2035: Explosive Study Links Mass Shootings to the Drug Industry Doping 20% of America | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast

Join Lionel on The Other Side of Midnight as he delves into the "seamy dark underbelly" of reality to find the dust bunnies the mainstream media ignores. In this episode, Lionel dissects the "conspiratorium" code, challenges the official narrative on Kurt Cobain's death, and questions the link between SSRIs and violent crime. From the "Kayfabe" of the justice system to the shadowy SES deep state, Lionel asks the question: "Why aren't they talking about this?" Learn more about your ad choices. Visit megaphone.fm/adchoices

Keegan Downer (Founder of mindfulMEDS) shares how he went from alcohol addiction and a near-suicidal breaking point, to recovery and to building one of Canada's most recognized microdosing education brands, and why psilocybin doesn't have to be "woo."  We also get super practical: What microdosing actually feels like day-to-day, why it can hit women differently (especially moms), how psilocybin compares to SSRIs (Selective Serotonin Reuptake Inhibitor) when it comes to emotional processing, and why "wine o'clock" culture is quietly keeping so many women stuck in a stress-and-numb cycle. Join my NEW private community at thelongherlife.com for ongoing protocols, live coaching, and deeper support. WE TALK ABOUT:  05:40 - Keegan's life collapse that led to addiction and the "rooftop moment"  07:45 - Rebuilding purpose after rehab and the anxiety attack that changed everything  09:10 - Why microdosing went from "nobody's talking about this" to mainstream fast  12:35 - The day-13 breakthrough and the microdosing study that launched his mission  19:30 - Why psilocybin and SSRIs create totally different emotional outcomes  23:20 - When microdosing feels "too strong" and how dose + setting change everything  28:40 - The dose reality check: "microdose" vs "creative dose" and why sensitivity matters  38:20 - Why women (especially moms) are the fastest-growing microdosing segment  41:05 - "Wine o'clock" culture, addiction masking, and the uncomfortable truth  44:00 - Brainbow: The saffron extract approach for mood, sleep, and nervous system support  57:10 - Where to learn more, the free microdosing guide, and weekly consults RESOURCES: Join my NEW private community at thelongherlife.com for ongoing protocols, live coaching, and deeper support. Join me in Costa Rica for Optimize Her, a 5-night luxury women's retreat with biohacking, yoga, healing rituals, and longevity workshops—only 2 spots left. Download the non-toxic baby registry guide to reduce toxic exposure and make confident, evidence-informed choices for your family—free. Mindful Meds website and Instagram Get The Mindful Meds Microdosing Guide here LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music  

In this conversation, the hosts ions, andeen dietary choices and ketosis levels, and clarify the differences between ketosis and ketoacidosis. The conversation also touches on insulin resistance, explaining it as a protective mechanism rather than a failure of insulin itself, and critiques the pharmaceutical approaches to managing these metabolic issues. In this conversation, the speakers delve into the dangers of SSRIs, the misconceptions surrounding cholesterol, and the misleading nutritional claims often made about foods like spinach. They discuss the importance of understanding bioavailability in nutrition, particularly regarding iron and vitamin C absorption, and highlight the profit-driven motives of the pharmaceutical industry, including the practice of creating 'satellite drugs' to maximize profits.Chapters00:00 Introduction and Greetings01:01 Understanding Ketosis and Its Fluctuations04:46 The Role of Continuous Monitoring in Ketosis06:28 Exploring Ketosis Levels and Dietary Impact10:50 Misconceptions About Ketosis and Ketoacidosis14:15 Insulin Resistance Explained18:42 Pharmaceutical Interventions and Their Implications21:40 The Dangers of SSRIs and Pharmaceutical Practices22:59 Debunking Cholesterol Myths27:55 The Truth About Nutritional Claims34:01 Understanding Vitamin C and Iron Absorption39:01 The Dark Side of Pharmaceutical Profitability

Have you ever heard of inositol? Could you be deficient and not even realize it? If you're struggling with blood sugar swings, irregular cycles, anxiety, or 2am wake-ups, could this overlooked compound be a missing piece? While magnesium, B vitamins, and electrolytes dominate most wellness conversations, myo-inositol plays a critical role in insulin signaling, ovarian function, and neurotransmitter balance, acting as an intracellular messenger that helps your cells properly respond to hormonal cues. This episode unpacks what myo-inositol actually is, how it functions in the body, and what the research shows in areas like PCOS, insulin resistance, fertility, mood disorders, and sleep. It also covers therapeutic dosing, food sources, and how to use supplementation strategically for clinical outcomes. Whether you're navigating hormone imbalance, metabolic dysfunction, or nervous system dysregulation, this conversation takes a deeper look at why myo-inositol deserves far more attention in root-cause medicine. Also in this episode: What is inositol? What does it do in the body? What causes myoinositol deficiency? Symptoms of deficiency Episode 470: SSRIs on the Rise: Concerns and Safer alternatives Episode 430: Keto and PCOS Inositol and Metabolic Health Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome | New England Journal of Medicine Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial - PubMed Potential role and therapeutic interests of myo-inositol in metabolic diseases - PubMed Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials - PMC  Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial - PMC The Comparative Effects of Myo-Inositol and Metformin Therapy on the Clinical and Biochemical Parameters of Women of Normal Weight Suffering from Polycystic Ovary Syndrome Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials - PubMed Full article: Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials Inositol for Mental Health Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder - PubMed Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder - PubMed Inositol treatment of obsessive-compulsive disorder - PubMed D-Chiro inositol vs. Myoinositol Food sources of inositol Dosage, safety and tolerability 1-2 scoops Relax and Regulate  This episode is sponsored by Naturally Nourished Relax and Regulate Relax & Regulate has always been a superstar for sleep, stress, and hormone support, and we've taken a good thing and made it even better! We've seen incredible results with 1000's of clients using Relax and Regulate literally every day for 10+ years now.    We have increased magnesium bisglycinate from 200 mg to 250 mg to match clinical sleep research dosing, kept myo-inositol at the full 4-gram therapeutic dose, and improved the supporting ingredients so the entire formula is better absorbed, better tolerated, and more aligned with what we're seeing clinically every day. Use code RELAX15 to save 15% on our reformulated Relax and Regulate! 

In the first hour of episode #1156, Clay Edwards fires up your Monday with raw motivation to rise, grind, and conquer the week. He shares his weekend highlights, including subscribing to the Angel Studios app for faith-based and conservative-leaning content, and highly recommends the must-watch documentary "Thank You, Dr. Fauci," unpacking COVID conspiracies, lab leaks, vaccine funding, and money-driven cover-ups with insights from scientists, journalists, and a former CDC head. Clay also dives into the post-apocalyptic thriller "Homestead" and its series, tying into real-world prepping discussions. A caller chimes in on methane facts and Mississippi court corruption, sparking thoughts on statewide issues. Teasing upcoming headlines like Amazon's Ring split, a Jackson restaurant brawl, education wins, and eerie Epstein Island links to SpongeBob. Plus, a fiery take on a Maryland school official reporting conservative teens to child services for starting a TPUSA club, exposing left-wing indoctrination fears. Unfiltered rants on liberal hysteria, SSRIs, and generational politics round out the hour—strap in for no-holds-barred reality radio.

In the second hour of episode #1156, Clay Edwards takes a deep dive into generational politics, exploring why Gen X has been largely sidelined in leadership roles, blaming boomers for clinging to power and delaying opportunities—now leaving many Gen Xers in their 40s and 50s too established in careers and family life to pivot. He breaks down stats on Congress (Gen X at 41% in the House but only 28% in the Senate) and Mississippi's legislature (average age 57, boomers dominant at 45%), urging Gen X to step up and counter liberal indoctrination. A caller sparks debate on holding teachers' unions accountable, pushing "feel-good" policies over core education, and infiltrating local politics. Clay unleashes unfiltered rants on liberal Gen Xers as the most offended and medicated group, SSRIs turning affluent white women "gay" (with satirical jabs at stereotypes), and the revival of racism by black Gen X post-Obama. He shares personal views on relationships, favoring driven partners over dependents, and stresses trade schools over useless college degrees. Wrapping with listener texts on anti-ICE protests, Gen X presidents, and positive solutions—pure, no-holds-barred commentary on culture, corruption, and America's soul.

Trish Wood on Canada before and after Tumbler Ridge. There is much to learn from this generational tragedy. The danger of SSRIs, the power of anti-psychotic drugs, and the folly of "trans-affirming psychotherapy" for self-diagnosing teenagers. Dangers we already know, but do nothing about. Watch and Read Trish on Substack Follow Trish on X @woodreporting Website: www.trishwoodpodcast.com 

In this conversation, Kelsi Sheren addresses the alarming youth mental health crisis in North America, highlighted by a tragic shooting incident involving a trans-identified shooter. She discusses the potential role of pharmaceuticals, particularly SSRIs and antipsychotics, in exacerbating mental health issues among adolescents. Sheren emphasizes the need for a critical examination of gender identity narratives and the over-medicalization of youth, calling for a societal shift towards understanding and supporting children's mental health without harmful interventions.Chapters00:00 Introduction to the Youth Mental Health Crisis00:45 The Tragic Shooting Incident03:43 The Role of Pharmaceuticals in Mental Health06:30 The Impact of Gender Identity on Youth10:47 The Dangers of Over-Medicalization12:00 The Call for Awareness and Change - - - - - - - - - - - -One Time Donation! - Paypal - https://paypal.me/brassandunityBuy me a coffee! - https://buymeacoffee.com/kelsisherenLet's connect!Youtube - https://www.youtube.com/@thekelsisherenperspectiveInstagram -  https://www.instagram.com/thekelsisherenperspective?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw%3D%3DX: https://x.com/KelsiBurnsInstagram: https://www.instagram.com/kelsie_sheren/Substack:  https://substack.com/@kelsisherenTikTok -   https://x.com/KelsiBurnsSUPPORT OUR SPONSORS - - - - - - - - - - - -MasterPeace - 10% off with code KELSI - http://www.MasterPeace.Health/KelsiKetone IQ- 30% off with code KELSI - https://ketone.com/KELSIGood Livin - 20% off with code KELSI - https://www.itsgoodlivin.com/?ref=KELSIBrass & Unity - 20% off with code UNITY  - http://brassandunity.com

If pain is a portal, what's on the other side? We invited functional pharmacist and men's health coach Rob Kress to help us challenge the default settings of modern care...more meds, more noise, less self. Rob shares how he moved from conventional pharmacy to a practice that blends functional medicine, clinical nutrition, and mind‑body work, and why the real turning point for so many men is a regulated nervous system and the courage to tell the truth.We dig into the moments most men avoid. The numbness that follows chronic stress, the swing between agitation and apathy, and the quiet stories they keep buried deep. Rob offers simple, practical resets like two minutes to breathe before a hard talk, a short burst of movement to discharge stress, and five minutes of daily silence to build safety and presence. From there, we unpack testosterone: when TRT helps, when it masks a deeper issue, and how thyroid, adrenals, sleep, alcohol, and cannabis shape libido and drive more than most realize.Our conversation gets real about America's medication reflex. SSRIs and benzos can bring relief, but they often mute feeling and complicate long‑term healing. Rob shares how to taper thoughtfully with breathwork, body‑based therapy, a good team and a plan.We also explore autism through a systems lens. Acetaminophen's impact on glutathione, the difference between folic acid and folate, the promise of folinic acid for speech in some kids, and how dairy may elevate folate receptor autoantibodies. It's not about single causes. It's about looking at every angle.We close with agency. Interview your doctors, curate a care team, and choose tools that align with your values. The path to health and healing is meant to be co‑creative. Show up for the meaningful work, focus on the what, and release the need to control the timeline. If this conversation recharged your curiosity, share it with a friend, leave a review, and subscribe. And check out our Patreon so you never miss an episode.https://www.patreon.com/c/seeyouontheothersideConnect with Rob here:www.instagram.com/robkressfrx?https://linktr.ee/robkressfrxhttps://www.functionalpharmacy.com/contact-rob Microdosify 10% OFF our trusted microdose supply!1:1 Discovery Calls Are psychedelics right for you on your healing journey? Book a discovery call to ask us anything. Support the showJoin our Patreon for exclusive content:https://www.patreon.com/seeyouontheotherside Our Website:https://linktr.ee/seeyouontheothersidepodcast

(featured photo shows David, his wife Yvonne, and son, Joey, when young) Meet the Incredible Dr. David Antonuccio, Part 2 of 2 Shrink, Songwriter, and Hero Today we continue our conversation with my dear friend and esteemed colleague, Dr. David Antonuccio, a true scholar, clinician, researcher, musician, and champion of scientific transparency. The Nicotine Patch Study David revisited his landmark research on the nicotine patch, a costly trial involving roughly 600 participants who were randomly assigned to receive either a real nicotine patch or a sham patch. The goals were to assess safety and efficacy. The safety data looked reassuring. However, the efficacy findings were unexpected: the placebo patch worked just as well as the active nicotine patch in reducing smoking. The sponsoring company published the safety data but refused to publish—and refused David access to—the efficacy findings, which showed no advantage for the nicotine patch. You can check the link to the NEJM article here.  David writes: "Notice the 48 week follow-up data were excluded in this paper despite the fact that they were available. That really annoyed me. I also now believe that the original version of the paper was ghostwritten and ghost analyzed by the industry folks.in other words.  I'm not sure that the authors ever had access to the "raw" data before they were analyzed." This was important because there was a decrease in smoking DURING the study among those wearing the patch, and getting their "fix" of nicotine that way. . . but what happened AFTER the study?  David writes: "Here is the link to the follow up paper that emphasized efficacy and included the 48 week follow-up data." Notice that this paper was not published until three years later, when the Nicotine Patch had already been heavily advertised and sold on the market. This early experience in his career revealed the tension between marketing interests which focus on sales, and scientific interests which focus on truth and transparency—a daunting and frustrating pattern that would emerge again and again in his career. Expert Testimony in a Tragic Criminal Case David then described expert testimony he provided in a deeply troubling legal case. A 72-year-old woman, happily married for 50 years and a respected kindergarten teacher, had recently been prescribed Paxil, along with Ambien and Ativan. She abruptly, and without memory, woke up in the middle of the night and stabbed her husband 200 times and was subsequently arrested for homicide. There was no jury trial; instead, a plea bargain was used to determine sentencing. Dr. David Antonuccio was called as an expert witness in her defense. He described Dr. David Healy's research documenting a significant increase in both suicidal and violent urges among some patients taking SSRIs, especially Paxil. He argued that this woman's bizarre behavior was consistent with a drug-induced dissociative or fugue state. Based in part on David's testimony, the charge was reduced to manslaughter, and the judge sentenced her to time served, allowing her to return home to her children. For more on this topic: David Healy's Research on SSRIs and Homicidal Urge SSRIs Called on Carpet Over Violence Claims Black Box Warnings and Patient Rights David also emphasized the urgent need to revise Black Box warnings to reflect the full range of possible toxic or dissociative effects of psychiatric medications—not just suicidality. He has long advocated for a Patient Bill of Rights to ensure scientific transparency and informed consent. A Surprising Conversation with Dr. John Nash David shared a fascinating personal story about calling Dr. John Nash, whose life inspired the award-winning film A Beautiful Mind. In the movie, Nash's recovery from schizophrenia  is portrayed as medication-dependent. However, Nash told David directly that this was not true—the medication narrative was added to the script, possibly out of concern that portraying his recovery without meds might discourage viewers from taking prescribed medications. Nash said: "What saved me was the support of family and friends." Music, Truth, and "Buzz" David is also a talented songwriter. One of his songs, "Buzz," addresses the emotional and ethical issues surrounding electroconvulsive therapy (ECT). The inspiration came from a man in the Midwest who was legally ordered to undergo ECT against his will. A widespread public outcry ultimately convinced the judge to rescind the order. Forgiveness and "In the Air Tonight" One of David's favorite songs is Phil Collins' "In the Air Tonight," which he sees as a deeply spiritual musical meditation on forgiveness—a theme David considers one of the most powerful psychological forces we possess. David explains that the Phil Collin's song is about forgiveness, but more indirectly and specifically about the songwriter's inability to forgive. And yes—David sang it live for us on the podcast! You might be interested in this chapter that David coauthored on the science of forgiveness Thank you for joining us today. And heartfelt thanks to you, Dr. David Antonuccio, for your gifts of enlightened skepticism, ethical courage, incisive scientific thinking, and soulful musical talent. David, Rhonda, and David

Have you tried magnesium but felt like it didn't help—or even made things worse? Are you confused by all the different forms and dosages? In this episode, Ali and Becki break down how magnesium actually works in the body, why so many people think they “don't tolerate” magnesium, and why form, dose, and context matter far more than most realize. We also share the full story behind the reformulation of Relax & Regulate, our superstar magnesium product. You'll learn why we chose magnesium bisglycinate paired with myo-inositol, how this combination supports nervous system regulation, sleep, anxiety, blood sugar, and hormone balance, and why it's especially impactful for PCOS, perimenopause, and stress-driven symptoms.  Also in this episode: Why is magnesium so important? Signs of magnesium deficiency Testing magnesium status Cell Science Systems Micronutrient Panel Episode 440 What does HTMA say about your health with guest Kaely McDevitt Anxiety and Magnesium Deficiency Naturally Nourished Episode 470 SSRIs on the Rise The magnesium GABA connection GabaCalm How inositol supports serotonin Why the combination of magnesium and inositol for blood sugar balance Why magnesium deficiency is more pronounced in perimenopause Forms of magnesium and absorption Considerations of magnesium threonate Why glycine matters and antiaging effects Naturally Nourished Episode 331 Homocysteine and Methylation Dosage considerations 1 scoop for maintenance 2+ scoops for PCOS, constipation, high cortisol, pregnancy Kids can start with ⅛-¼ scoop as early as age 2-3 Teens ½-1 scoop to start for acne, anxiety, hormonal concerns This episode is sponsored by Naturally Nourished Relax and Regulate Relax & Regulate has always been a superstar for sleep, stress, and hormone support, and we've taken a good thing and made it even better! We've seen incredible results with 1000's of clients using Relax and Regulate literally every day for 10+ years now.    We have increased magnesium bisglycinate from 200 mg to 250 mg to match clinical sleep research dosing, kept myo-inositol at the full 4-gram therapeutic dose, and improved the supporting ingredients so the entire formula is better absorbed, better tolerated, and more aligned with what we're seeing clinically every day. Use code RELAX15 to save 15% on our reformulated Relax and Regulate!

This episode is a raw, unscripted deep dive into men's mental health, toxic masculinity myths, anxiety, depression, fatherhood, money stress, and why modern mental health systems continue to miss men entirely. Using recent Psychology Today articles and peer reviewed research, the conversation breaks down what toxic masculinity actually is, how rare it truly is, and why buzzwords without clear definitions are doing more harm than good. You'll hear real talk on why most men are not toxic, how anxiety often shows up as anger or withdrawal, and why many men feel misunderstood or dismissed by traditional therapy models. You can expect honest commentary on male vulnerability, financial pressure, provider identity, SSRIs, plant medicine, trauma, fatherhood, and why men struggle in silence until things fall apart. This episode challenges pop psychology, questions mainstream narratives, and opens up a much needed conversation about what men actually need to heal, lead, and stay present for their families. If you care about men's mental health, masculinity, relationships, fatherhood, purpose, or breaking generational patterns, this video will hit hard and make you think long after it endsDisclaimer: We are not professionals. This podcast is opinioned based and from life experience. This is for entertainment purposes only. Opinions helped by our guests may not reflect our own. But we love a good conversation.Become a supporter of this podcast: https://www.spreaker.com/podcast/2-be-better--5828421/support.

Ginny Yurich sits down with Dr. Nicole Cain—author of Panic Proof—for a conversation that makes anxiety feel less mysterious and a whole lot more workable. Nicole explains why panic is often protective, how to spot your early “pay attention” signals before you hit crisis mode, and why the same tool won't always work. You'll come away with practical ideas like building a “panic pack,” using cold to calm the nervous system, and simple brain-and-body resets that matter even more in a screen-saturated world. They also go deeper on hormones, sleep, SSRIs, and why creativity and movement can be real medicine especially for kids. Learn more about Dr. Cain and her work at drnicolecain.com, get a copy of her book Panic Proof, and check out her podcast Holistic Inner Balance. Learn more about your ad choices. Visit megaphone.fm/adchoices

#307 Raul Pastrana is a degree-qualified naturopath specializing in fertility and reproductive health, with a particular focus on male fertility—an area that's often overlooked in the fertility conversation. He works closely with individuals and couples through preconception care, IVF preparation, and natural conception, creating tailored treatment plans based on semen analysis, blood pathology, and each person's unique circumstances. Raul is the author of The Male Factor: Fertility is a Shared Responsibility, where he explores how men can actively influence fertility outcomes and provides practical strategies to improve sperm health. Drawing on his background as both a naturopath and personal trainer, Raul has a gift for translating complex health information into actionable changes that people can actually integrate into their daily lives. He is passionate about shifting the narrative around fertility from being solely a "women's issue" to recognising it as a shared responsibility that requires equal investigation and treatment for both partners. In this episode, we cover: Why male factors contribute to at least 50% of infertility cases, yet women carry the burden of investigation and treatment  How sperm health impacts not just conception, but pregnancy loss, complications, and long-term child health The 72-74 day sperm production cycle and why this gives men unique leverage to improve outcomes quickly What's actually being measured in a semen analysis—and why "normal" reference ranges are based on the 5th percentile DNA fragmentation: the critical test that's often overlooked and what it reveals about fertility potential The main factors that influence sperm health: medications (SSRIs, finasteride, ibuprofen), alcohol, antibiotics, and lesser-known culprits The seminal microbiome: what healthy versus dysbiotic looks like and how gut health influences reproductive health Real case studies of dramatic sperm improvements after addressing underlying factors Why proper testing and preconception care matter even when pursuing IVF   If you or someone you know is navigating fertility challenges—or simply wants to optimize reproductive health—this episode offers practical, evidence-based insights that could change outcomes.     Pre-order The Male Factor: https://www.rhreproductivehealth.com/bookstore Rauls website https://www.rhreproductivehealth.com/our-team , Rauls instagram https://www.instagram.com/raulpastrana_hormonalhealth/?hl=en   WORK WITH ME: Book a 1:1 Consultation: https://www.lyndagriparic.com/book-an-appointment/  Shop BetterMe Tea: https://www.lyndagriparic.com/shop/ Website: https://lyndagriparic.com Instagram: https://www.instagram.com/lynda_griparic_naturopath/     This content is for educational purposes only and is not intended as medical advice.

In this episode, we explore a critical drug interaction: SSRIs combined with anticoagulants increase major bleeding risk by 35-47%. Should age and sex change our prescribing decisions? We break down the evidence from nearly 100,000 patients and discuss safer antidepressant alternatives for high-risk individuals. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 77 Do SSRIs Increase Major Bleeding Risk with Oral Anticoagulants?

#197 - How to Reverse Bone Loss Naturally — With 4 Clinically Proven Nutrients to Prevent Fractures. Interview with Dr. John Neustadt   Why Calcium Isn't the Answer to Strong Bones (and What Actually Is) — with Dr. John Neustadt If you've ever been told, “Just take calcium for your bones,” this episode is going to blow your mind. Lisa sits down with Dr. John Neustadt, naturopathic doctor, bestselling author of Fracture-Proof Your Bones, and founder of NBI Health, to uncover what really causes — and reverses — osteoporosis. It turns out, bone health isn't just about bone density. And the scary truth? The standard “treatments” may actually make bones more brittle. From medication-induced bone loss to how to choose supplements that actually work (and aren't a waste of money), Dr. Neustadt breaks down the science in a way that's refreshingly clear — and shockingly empowering. You'll learn:

Welcome to Resiliency Radio with Dr. Jill Carnahan, where today's episode takes you behind the scenes of ketamine therapy—one of the most promising and misunderstood breakthroughs in modern mental health care. Dr. Jill is joined by Dr. Jennifer Ellice, a board-certified emergency medicine physician and founder of Golden Afternoon Clinic. In this candid and eye-opening conversation, Dr. Ellice shares her unconventional journey from emergency medicine burnout during COVID to specializing in trauma-informed ketamine therapy for treatment-resistant depression, anxiety, PTSD, chronic pain, and suicidal ideation.

Dr. Read Montague, PhD, is a professor and director of the Center for Human Neuroscience Research at Virginia Tech and an expert in how dopamine and serotonin shape human learning, motivation and decision-making. We discuss how they impact focused effort in the context of short- and long-term goals of all kinds. Also, how SSRIs and low-effort, high-engagement activities reduce the rewarding properties of dopamine, and how AI algorithms are revolutionizing understanding of the brain. Episode show notes are available at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Joovv: https://joovv.com/huberman Function: https://functionhealth.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00:00) Read Montague (00:02:54) Dopamine, Motivation & Learning (00:08:49) Reward Prediction Error, Expectations (00:12:24) Sponsors: David & Joovv (00:14:54) Foraging, Dating, Expectations vs Outcomes; AI (00:23:36) Dopamine, Expectation, Motivation; Forward Drive; Dopamine "Hits" (00:29:58) Baseline Dopamine & Fluctuations; Parkinson's Disease (00:34:36) Movement, Urgency; ADHD, Bee's Dance, Explorer vs Focus Mode (00:42:29) Sponsor: AG1 (00:43:40) Social Media, ADHD; Explorers vs Task-Based, Combat (00:50:54) Effort, Learning; Social Media & Phones, Resisting Behaviors (01:01:36) Serotonin & Dopamine, Opponency, SSRIs (01:11:21) Hunger, Dopamine; Negative Feedback, Learning, Trauma; Torture (01:18:34) Drugs of Abuse & High Dopamine (01:19:48) Sponsor: Function (01:21:35) Trauma & Dopamine Adaptation (01:27:34) SSRIs, Dopamine, Positive Experiences (01:29:50) Deep Brain Stimulation; Measuring Dopamine & Serotonin in Humans (01:36:16) Sleep; Divorce; Science is a Contact Sport (01:45:14) Long-Term Motivation, Learning How to Fail, Tool: Kids & Sports (01:54:14) Sponsor: LMNT (01:55:34) Meditation, Breathing, Learning; Dopamine as a Currency (02:04:38) Function of Sleep, Motivation; Time Perception & Dopamine, Tracking Time (02:13:18) LLMs, AI, Uses & Problem Solving (02:18:33) Future Projects, Commercial Brain-Machine Interfaces; Concentration (02:25:57) Dopamine "Hits"?; Depression & Schizophrenia; Quitting (02:30:17) Dopamine & Serotonin Misunderstandings; Internal Satisfaction; Motivation (02:35:58) Serotonin Syndrome; Acknowledgements (02:38:31) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Alecia explores the critical intersection of women's mental health, ADHD, and reproductive psychiatry—an area where science is only beginning to catch up with women's lived experiences. Alecia's journey into psychiatry began in Sacramento, California, where she witnessed profound disparities in healthcare access across diverse communities. After seeing loved ones struggle with both physical and mental illness, she pursued medicine with a mission. During medical school, she gravitated toward geriatric psychiatry, drawn to the complexity of caring for older adults. But during residency, her focus began to shift as she became fascinated by something even more fundamental: the intricate dialogue between mind and body. This growing interest led her to consultation-liaison psychiatry, formerly known as psychosomatic medicine, where she served as chief resident. The field gave her a lens to understand how physical illness shapes mental health and vice versa—a perspective that would profoundly inform her later work. She went on to complete a consultation-liaison psychiatry fellowship at the University of Chicago, followed by specialized training in reproductive psychiatry. Alecia's attention to health disparities guided her toward women's and minority mental health, populations that remain vastly underfunded and underresearched. In her clinical work, she began noticing a troubling pattern: many patients struggling financially, physically, and emotionally actually met criteria for ADHD, yet had never been properly identified or treated. These missed diagnoses often compounded existing challenges, leaving people to navigate life with an invisible burden they didn't understand. In our conversation, Alecia illuminates why girls with ADHD are so often overlooked. While boys typically display hyperactive, disruptive symptoms that demand attention, girls more commonly present with inattentiveness—daydreaming, losing track of conversations, internal restlessness—symptoms easily misattributed to anxiety or depression. This diagnostic blind spot means girls are less likely to receive appropriate medication and more likely to struggle silently through years of self-blame. Alecia then guides us through the remarkable role hormones play in ADHD across the female lifespan. She explains how estrogen acts as a neuroprotective force, supporting the neurotransmitter systems that govern focus and impulse control. During the menstrual cycle, as estrogen and progesterone fluctuate, women with ADHD experience predictable shifts: heightened impulsivity and hyperactivity when estrogen dips after ovulation, and increased inattention, depression, and anxiety when both hormones plummet before menstruation. Strikingly, about sixty percent of women with ADHD also meet criteria for Premenstrual Dysphoric Disorder, underscoring just how intertwined hormones and mental health truly are. The postpartum period presents another vulnerable window. When estrogen declines after delivery, previously manageable or even unrecognized ADHD symptoms can suddenly intensify, leading to new diagnoses during what is already a demanding transition. Alecia thoughtfully discusses navigating stimulant medication during pregnancy, emphasizing that treatment decisions must honor each woman's unique circumstances while weighing risks and benefits for both mother and baby. As women approach perimenopause and menopause, declining and erratic estrogen levels can trigger cognitive changes, mood shifts, and worsening ADHD symptoms—yet clinical guidelines for diagnosis and treatment in this population remain virtually nonexistent. Alecia addresses the ongoing debates around hormone replacement therapy, noting that timing matters: estrogen therapy initiated earlier may offer benefits with fewer risks than when started later in life. She also discusses how certain SSRIs may help manage perimenopausal symptoms by supporting neurotransmitter function. What emerges most powerfully from this conversation is Alecia's compassion and her insistence on one fundamental principle: believe women. Listen to their experiences. Include their families in care. The science, she acknowledges, still has considerable catching up to do—but in the meantime, women deserve to be heard, validated, and treated with the individualized, evidence-informed care that respects the full complexity of their lives. Alecia Greenlee, MD, MPH is a board-certified psychiatrist who brings both rigorous training and deep humanity to her work with women navigating ADHD and co-occurring mental health conditions. After earning her medical degree from UC San Francisco, she completed her psychiatric residency at Harvard Medical School/Cambridge Health Alliance, where she served as chief resident in consultation-liaison psychiatry and developed expertise in collaborative care and mental health services for vulnerable populations. She went on to fellowship training at the University of Chicago, first in consultation-liaison psychiatry and then in reproductive psychiatry, gaining specialized knowledge in how the body and mind interact throughout women's lives. Allecia specializes in comprehensive psychiatric evaluation and evidence-based treatment for adults, with particular expertise in how hormonal changes throughout the female lifespan—from menstrual cycles to pregnancy to perimenopause—influence ADHD symptoms and overall mental health. Her commitment to health equity drew her to focus on women's and minority mental health, populations often underserved by research and clinical resources. She approaches each patient with cultural attunement and warmth, creating collaborative, safe spaces where people from all backgrounds feel genuinely heard. Her practice reflects a commitment to whole-person care that considers not just psychiatric symptoms, but the complex interplay of biology, identity, life circumstances, and medical conditions that shape each individual's treatment needs.

SSRI antidepressants are one of the most harmful medications on the market, and because of just how many people they are given to (often for no good reason as only a minority of patients benefit from SSRIs) they have had a profound effect on the consciousness of our entire society This article will review some of the more common side effects of SSRIs (and SNRIs), such as losing the ability to have sex, becoming numb to life, becoming severely agitated or imbalanced (sometimes to the point one becomes violently psychotic or commits suicide), losing your mind, and the development of birth defects Like many other stimulant drugs (e.g., cocaine) SSRIs can be very difficult to quit. Because of this, patients frequently get severely ill when they attempt to stop them (withdrawals affect roughly half of SSRI users). Worse still, it is often extremely difficult to withdraw from them and very few doctors know how to safely facilitate this Due to widespread denial in psychiatry about the issues with their drugs the common SSRI side effects (e.g., withdrawals) are often misinterpreted as a sign the individual had a pre-existing mental illness and needs more of the drug — which all too often then leads to catastrophic events for the over-medicated patient This article will provide the critical information SSRI patients are rarely warned about and resources for patients already trapped in challenging mental health situations  

Dr. Joanna Moncrieff is a British psychiatrist and author of “Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth.” She challenges the long-held belief that depression is caused by a lack of the hormone serotonin.“The serotonin myth … was first put out there in the 1960s, then picked up by the pharmaceutical industry in the 1990s and widely propagated by them as part of their campaign to sell SSRIs, their new generation of antidepressants,” she said.Contrary to what many people still believe, there's no evidence that depression is caused by a lack of serotonin in the brain, Moncrieff said.“A few years ago, we published what's called an umbrella review, a sort of meta review of all the different areas of research that have looked at this. … And we show that there is no consistent or convincing evidence in any of these areas of research for any association between serotonin and depression. So hence, the idea is a myth,” she said.In our interview, she explains how this narrative took hold and how it reshaped modern psychiatry.So what causes depression if not a lack of serotonin? Dr. Moncrieff, who is a professor of critical and social psychiatry at University College London, regards depression as “meaningful human reactions to the circumstances of life now, and that is indeed how people used to think about them.”It's not a biological disease, she said, but a normal reaction that anyone may experience at times throughout life.“It's not something that we naturally just get over in a couple of weeks. It can take weeks and months of grieving, even for a short-term relationship that's finished.”To label deep sadness as a pathological medical condition that needs to be fixed with drugs is the wrong approach and precludes seeing a person “who is suffering, who is going through a period of difficulty and trying to work out what that is and how we can support them with it,” Moncrieff said.Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

Three facts are scientifically undisputed: Serotonin is essential for fetal brain development. SSRIs disrupt the serotonin system. SSRIs freely cross the placenta. So why are pregnant women being told these drugs carry "little or no risk"?In this rare head-to-head debate, Dr. Adam Urato—maternal-fetal medicine specialist and FDA expert panelist—faces off against Dr. Robert Chen, a psychiatry resident willing to do what most of his colleagues won't: step into the arena and defend the establishment position.What unfolds is a striking conversation where both physicians actually agree on more than you'd expect—including that informed consent is failing pregnant women, that the chemical imbalance theory is dead, and that "untreated depression" is a misleading frame designed to sell drugs. The uncomfortable question neither side can fully answer: If SSRIs are correcting depression, why does the research show worse outcomes for women who stay on them?This isn't anti-medication propaganda. It's the conversation your doctor isn't trained to have with you.Listen before you fill that prescription. Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

As 2026 gets underway we know that many take time around this new beginning to improve not only their physical, but also their mental health. With that in mind, we're rerunning an episode with Leanne Williams on the future of depression care. Leanne is an expert on clinical depression and is working on new ways to more precisely diagnose depression in order to develop more effective treatment. For anyone who has suffered from depression or knows someone who has, it's an episode that provides hope for what's on the horizon. We hope you'll take another listen and also share this episode with anyone who you think may benefit from the conversation. Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:01:43) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:03:31) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their timelines.(00:06:16) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:03) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:22) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging.(00:12:31) Cognitive Features of DepressionHow cognitive impairment plays a major role in certain depression biotypes.(00:14:11) Matching Treatments to BiotypesFinding appropriate treatments sooner using brain-based diagnostics.(00:15:38) Expanding Treatment OptionsPersonalizing therapies and improving treatment outcomes based on biotypes.(00:19:03) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:15) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:23:46) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:29) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:29:38) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The anti-ICE protests, sparked by the fatal shooting of Renee Good, presently happening throughout the USA, don’t appear to be dying down. So why does it appear to be mostly white women protesting? There are several theories as to why that is, but one is that a lot of these women are unmarried and childless but still have the instinct to mother, so they see ICE agents as their ex-husbands and the illegal immigrants as the children they don’t have. Plus, they’re sick and thus overly medicated on a chemical cocktail of antidepressants and SSRIs. The ICE agents are there to do their job, which is to enforce the law, and process warrants for people who are in the country illegally. So why are so many white women angry about it? Listeners certainly have their opinions about why this is. Meanwhile, what’s with all the whistles?See omnystudio.com/listener for privacy information.

Dr. Keith Humphreys is a professor of psychiatry and behavioral sciences at Stanford School of Medicine and a leading expert on treating addictions, drug laws and policy. We discuss all the major addictive substances and behaviors, including alcohol, opioids, gambling, stimulants, nicotine, cannabis and more, focusing on how genetics and certain use patterns shape addiction susceptibility. We discuss the best evidence-based tools for recovery, from 12-step programs to emerging treatments such as psychedelics and ibogaine. Anyone interested in making better choices for their health and/or seeking to avoid or overcome addictions ought to benefit from this episode. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00:58) Keith Humphreys (00:03:22) Addiction; Genetic Risk (00:09:14) Alcohol Use Disorder & Alcoholism; Genetic Predisposition & Addiction Risk (00:18:03) Sponsors: David & BetterHelp (00:20:37) Women & Alcohol Use; Young Adults; Cannabis Use (00:23:36) Health Benefit to Alcohol?, Red Wine, Cancer Risk; Social Pressure (00:31:47) Alcohol in Social Gatherings, Social Anxiety, Vulnerability, Work & Dates (00:37:41) Old vs New Cannabis & THC Levels; Smoked vs Edible Forms (00:44:38) Cannabis & Psychosis Risk; Cardiac Health; Youth Cannabis Use & Transition to Adulthood (00:52:29) Sponsor: AG1 (00:54:13) Industries of Addiction, Regulation; Gambling, Slot Machines, Novelty; Casinos (01:05:28) Decriminalization vs Legalization; Cannabis, Gateway Drug? (01:08:50) Psylocibin or LSD, Addiction Treatment; Microdosing, Clinical Trial Challenges (01:18:58) Sponsor: Helix Sleep (01:20:32) Brain Plasticity & Age; Ketamine, Depression, Transcranial Magnetic Stimulation (TMS) (01:28:10) SSRIs, Mass Shootings, Suicide, Side Effects; Drug Approval; Ibogaine & PTSD (01:36:10) Caffeine Addiction?; Stimulants & Rehab; Prescription Stimulants & ADHD (01:44:04) Nicotine, Mistaking Withdrawal for Benefit (01:47:24) Sponsor: LMNT (01:48:44) Tool: How to Talk to Someone with Addiction (01:55:23) Perception of Addicts, Character Defect, Pain (02:00:58) Overcoming Addiction, Immediate Rewards, AA; Addict & Co-Dependency? (02:09:53) Longterm Drug Use, Dopamine, Cues & Relapse; Social Media (02:16:21) Brain Stimulation, TMS; Homelessness, Substance Use & Rehab (02:26:11) Addiction Treatment Policy, Rehab & Insurance (02:29:08) Tool: 12-Step Programs, AA, Accessibility & Benefits (02:38:08) AA, Higher Power, Cult?; Flexibility, Tool: Open AA Meetings (02:44:38) GLP-1s, Weight Loss, Alcohol Addiction; Pharmaceutical Advertisements (02:52:39) Social Media Addiction, Tool: Avoiding Social Media Strategies (02:58:36) “Failure to Launch”, Youth, Video Games, Social Media; Recovery Pathways (03:04:13) AA as an Action Program, Tool: Try Different AA Meetings (03:08:21) Hospice, Death, Overcoming Fear of Death (03:13:54) Addiction to Escape Death?, Desire for Oblivion (03:18:11) Men vs Women & Addiction; Lying; Relapse; Fentanyl & Addiction Advice (03:24:27) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Contributor: Taylor Lynch, MD Educational Pearls: What is tramadol and how does it work? Tramadol is a Schedule IV opioid analgesic used for moderate pain and is often perceived as safer than other opioids due to lower abuse potential. It is a prodrug with weak direct μ-opioid receptor activity. The parent compound also inhibits serotonin and norepinephrine reuptake, giving it SSRI/SNRI-like properties. Tramadol is metabolized by CYP2D6 into O-desmethyltramadol (ODT), which has significantly stronger μ-opioid receptor agonism than the parent drug. What are the concerns with tramadol? Ultrarapid CYP2D6 metabolizers (more common in Middle Eastern and North African populations) rapidly convert tramadol to ODT, increasing the risk of opioid toxicity. Poor CYP2D6 metabolizers generate little ODT and may experience primarily serotonergic effects, increasing the risk of serotonin syndrome, especially when combined with SSRIs or SNRIs. CYP2D6 inhibitors (e.g., bupropion, paroxetine, terbinafine, celecoxib) can block tramadol's conversion to ODT, potentially precipitating opioid withdrawal or increasing serotonergic toxicity. Tramadol is also associated with an increased risk of first-time seizures, even at therapeutic doses. Key takeaways Tramadol's effects are highly unpredictable, varying from minimal analgesia to exaggerated opioid effects depending on metabolism. Drug–drug interactions can lead to serotonin syndrome or opioid withdrawal. Despite its Schedule IV classification and reputation for safety, alternative analgesics may be preferable in many patients. References DailyMed - TRAMADOL HYDROCHLORIDE tablet, coated. Accessed January 10, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61fb5ba7-6896-4ee4-83de-caee69b06a8e#ID57 Dean L, Kane M. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. National Center for Biotechnology Information (US); 2012. Accessed January 10, 2026. http://www.ncbi.nlm.nih.gov/books/NBK315950/ Aly SM, Tartar O, Sabaouni N, Hennart B, Gaulier JM, Allorge D. Tramadol-Related Deaths: Genetic Analysis in Relation to Metabolic Ratios. J Anal Toxicol. 2022;46(7):791-796. doi:10.1093/jat/bkab096 Summarized and edited by Dan Orbidan OMS2 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf  

Dementia is often a highly burdensome disease process for patients, their caregivers and families, and the community at large. Palliating symptoms and providing guidance surrounding advance care planning and prognostication are integral components of the management plan. In this episode, Katie Grouse, MD, FAAN, speaks with Neal Weisbrod, MD, an author of the article "Neuropalliative Care in Dementia" in the Continuum® December 2025 Neuropalliative Care issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Weisbrod is a neurologist at Hartford Healthcare with the Ayer Neuroscience Institute in Mystic, Conneticut. Additional Resources Read the article: Neuropalliative Care in Dementia Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Neal Weisbrod about his article on neuropalliative care in dementia, which appears in the December 2025 Continuum issue on neuropalliative care. Welcome to the podcast, and please introduce yourself to our audience.  Dr Weisbrod: Thank you. I'm really excited to be here. I'm Neal Weisbrod. I'm a neurologist and palliative care physician currently working at Hartford Healthcare in Mystic, Connecticut. Dr Grouse: To start, I'd like to ask why you think it's important that neurologists read your article? Dr Weisbrod: The primary reason I think it's really important to read the article is because these are just really common problems that neurologists run into in clinical practice. So, Alzheimer disease and many other dementias are extremely common, and managing the burdensome symptoms and the complex discussions that we have to have with the patients and their families as they go through the course of dementia is something that is very common in clinical practice. And so my hope is that by reading this article, clinicians will pick up a few tools, a few new ideas for how to make these conversations easier and for how to help these patients get through the disease with a little bit less suffering. Dr Grouse: I learned a lot from reading your article, and I really encourage our listeners to check it out. But I was curious what you feel that you discussing your article would come as the biggest surprise to our listeners? Dr Weisbrod: So, I think that the most surprising thing a lot of people will see reading this article is the section on prognosis. A lot of times it seems families are counseled, when they're talking about the prognosis of Alzheimer disease, that it could be ten years or longer. But really, the data show that for many patients, the median prognosis is closer to three to eight years. And that is a little bit longer for Alzheimer disease than many other types of dementia, but also gets significantly shorter as patients get older. So, we're looking at a closer to three-year median prognosis for patients who are over eighty-five, whereas patients in their sixties are probably closer to the eight or nine-year median prognosis. And so I think that piece will hopefully help people give a little bit more accurate counseling about prognosis.  Dr Grouse: I'm glad you brought that up because I was wondering, why is it so important that we are careful to make sure that we're giving prognostic information for our patients and maybe even updating it as their clinical status changes? Dr Weisbrod: I think first of all, it's a really common thing that patients and families are thinking about and worried about. They don't necessarily always seem to ask as much as they want to know. I think there's a lot of fear around that conversation, even though it's really important. And then there's also often tension between the family and caregivers tend to want to know more than patients do. I think that it really helps people plan for the future as well as possible to know what their future might be. And we have a lot of limitations in predicting the future, but using the best information we can, laying out what we think the likely range is, allows people to make a lot more clear plans for their future. Dr Grouse: I'd imagine it's also pretty helpful for hospice referrals, too, having that data.  Dr Weisbrod: Yeah, definitely. And there's a lot of angst about when to refer patients who have dementia to hospice. The most important thing I think about when I'm making a hospice referral is that I don't have to be right. And I think it takes a lot of that concern off to just say, all I'm doing is making a connection, getting someone who's potentially interested in the hospice, who has a really advanced serious illness connected to a hospice agency. And then they can go through the full evaluation with the hospice and the hospice medical director and determine whether they're eligible. So, I think there are really helpful thresholds to think about that would be a good trigger. Like a patient who we think has advanced dementia, who has a hospitalization for pneumonia or a fracture of the hip or some other really serious acute medical condition, I think is a really good trigger to start to think about hospice. But most importantly, it's just the connection, and I tell the patients that upfront. I tell them that you're going to have a conversation and we'll decide whether you're a good fit, and if not, the hospice will usually just check in with you over time and decide when is the right time in the future. Dr Grouse: That's really helpful. And I think just a really great reminder to our listeners about thinking about hospice sooner or at certain critical points in their patient care rather than waiting, maybe, before it's gone on too long and may be of less use later on. I was wondering, in your own clinical practice, what do you think is the most challenging aspect of providing care to patients with dementia?  Dr Weisbrod: I think this one's easy. I would say managing the time has to be the most difficult part. I think that taking care of patients who have dementia is time-consuming. There's a lot of different priorities that we have to manage the time around. How much time are we going to spend doing cognitive testing? How much time are we going to spend doing counseling? How much time are we going to spend making up a treatment plan and discussing medications? How much time are we going to spend on advanced care planning? And the way I try to combat that is really just trying to think about what I'm going to prioritize in a certain visit and not try to accomplish everything. I'll tell patients and their families, the next time you come in, we're going to have a conversation focusing on advanced care planning. Or, the next time you come in, we're going to sit down and try to talk through all the questions you have about what the future might hold. That way I in that visit, I don't feel like, oh, I have to do updated cognitive testing and I have to review all the next steps in medication, and that allows me to take it in more bite-sized chunks. Dr Grouse: You made some of the great points, and specifically you mentioned advanced care planning. Your article makes a really strong case for the importance of advanced care planning, yet you definitely acknowledge the many barriers to initiating discussions that clinicians face. In your patients with dementia, can you walk us through how you integrate discussions about advanced care planning with your patients and their families?  Dr Weisbrod: Yeah, I think this is still something that is evolving in my practice, and I don't think there's any perfect way of doing it. I think there's a lot of right ways of doing it, and as long as we're thinking about it a lot and bringing it up periodically, that's probably the best. What I try to do, though, is after I discuss what I think is the most likely diagnosis with patients and their families, I try to have a fairly close follow-up visit after that. Allow them to digest that information, to often do a little bit of their own research, to talk about it as a family. And then when they come in for that next appointment, I try to at least lay some groundwork about advanced care planning, asking them what they've completed already, and then based on what they've already done to that point, talking to them about what I think the next step would be. If they have done nothing, usually it's just, hey, I really think you should start to think about who would be making decisions for you if you lose the ability to make your own decisions and counsel them about power of attorney paperwork and establishing a healthcare surrogate. When it's patients who have already done some of that initial prep, I think that it's really important to keep in mind it's a longitudinal discussion and you can take it in small pieces over time. Often that helps because you can really establish that rapport and that trust. And then I like to just keep checking in whenever there's major changes in the patient's health or condition, like admission to the hospital or transfer to an assisted living facility or memory care clinic. Those are good times to remember, hey, I really need to revisit this conversation.  Dr Grouse: It's probably good to also mention another really important point from your article, which was that impairment of decision-making in patients with dementia can actually start significantly even in the phase of mild cognitive impairment. Yet these patients will need to make many medical decisions with their neurologist as they go through this journey. How can we make sure our patients have capacity and make decisions appropriately regarding their care? Dr Weisbrod: Yeah, I think that's a definite challenge of taking care of patients with cognitive disorders of any type, including those with stroke and multiple sclerosis, that have some cognitive impairment. In my opinion, the most important way to help manage that is to make sure when we are making important decisions about the future that we're having a deep exploration of the values and the reasoning behind that. And definitely teach back is the most helpful way that I use to explore those values and the logic behind patients' decisions. So, I think we have to have a really low threshold to move on to a formal evaluation of capacity; if there's any inconsistency between what the patient's saying now and what their families say they've said in the past, or if they're having struggled to come up with a really clear logic behind their decision, then I think we have to have a low threshold to move on to a formal evaluation of capacity. So, I think having the family involved, having other people who know the patient really well, usually helps identify some of those periods where it seems like the patient's not making the decision that really reflects their true wishes. Dr Grouse: Now I wanted to switch gears a little bit and get into the management of neuropsychiatric symptoms, which you spend a lot of time on and I think a lot of neurologists find very challenging. What are some nonpharmacologic approaches that can help patients with significant neuropsychiatric symptoms?  Dr Weisbrod: I really like the DICE paradigm for coming up with nonpharmacologic approaches. The DICE paradigm is an acronym. The D is Describe, I is Investigate, C is Create, and E is Evaluate. The idea is that we're exploring what's happening behind the symptoms, we're creating a plan to intervene, and then we're evaluating the outcome of that plan and creating a sort of feedback loop there. But ultimately, I think, when we're creating a solution, thinking about how we can change the environment is the most important thing. We have very limited ability to change the way that someone who has severe cognitive dysfunction reacts to their environment, but we can often change the environment to not produce that reaction in the first place. One example is with wandering behaviors. Trying to change the environment where you put locks that don't have deadbolts that you can use on the inside of the house, you have to have a key on the inside of the house, and then the family can put that key somewhere safe where the patient is not likely to find it and be able to unlock the door and wander out unsafely. I also think it's really important to acknowledge that as doctors, we are maybe not the best people to always have the answer when it comes to changing a patient's environment. And so, I think we really need to rely on the wisdom of support groups and other people who are going through the challenge of dementia. Our interdisciplinary care teams like social workers and nurses who have experience in managing dementia, and really try to plug the caregivers into as many of these avenues as possible so that they can learn from all of that community of wealth and not always rely on the doctor to have the answer. Dr Grouse: Switching gears to pharmacologic management, which is a lot of what we do for patients as neurologists. Thinking about agitation, pharmacologic management of agitation can be very challenging. And reading your article, it reminds me how disheartening it is to reflect and how modest the effect of the available options are, along with the many potential risks of their use, When nonpharmacologic interventions fail, what should neurologists recommend for their patients with agitation? Dr Weisbrod: Yeah, I definitely agree. It's every time I go back and look at this literature and look at what's new, it is a bit disheartening. But even in the face of all that, I really feel like SSRIs are my first-line therapy for most of these patients. I always try to ask myself what might be causing the patient discomfort that they are then manifesting as agitation because they don't have a better way of expressing themselves. Often, I feel like that's anxiety or depression or some other psychological symptom that we might be able to address with an SSRI. So, I tend to use sertraline and escitalopram, start those early and as long as patients are tolerating it, give it a really good trial. Outside of that, escalating to other pharmacologic approaches, even though there's such controversy in the data about antipsychotics and even though there are very real risks, sometimes I think we essentially do need a chemical sedative. And I think that it's important to have a very frank conversation upfront with the caregivers and the medical decision maker for that patient. Make sure we are counseling them on the risk, the increased risk of mortality, and also to make it a time-limited trial. So, I think that saying we're going to try this medication (if the patient's decision maker agrees, obviously) for a month or two months or three months. But I definitely wouldn't want them to just have an open-ended plan where they're going to stay on it indefinitely. It should have some end point where we say, hey, is this working or not? And if it's working, then we'd make a decision, is the improvement in quality of life worth the risks? And if we're not seeing that improvement, then we definitely need to stop it. Dr Grouse: That seems very reasonable. And then thinking more towards some of the other types of symptoms that can be really challenging, I was really surprised to see how often uncontrolled pain is a significant contributor in patients with dementia. And certainly, both uncontrolled pain and poor sleep can worsen cognitive function and neuropsychiatric symptoms in general. But of course, there's ongoing concerns about side effects of these therapies and how they can also potentially worsen things. How should we be approaching management of pain and insomnia or poor sleep in these patients?  Dr Weisbrod: I think the key is just to start with really low burden treatments and escalate carefully and start with low doses of higher risk medications. So, when I think the low burden treatments for pain, scheduling acetaminophen, 1000 milligrams every eight hours, seems like a trivial thing to do, maybe? But it's actually surprising how much scheduled acetaminophen can take the edge off of pain and might be able to avoid some of these flare-ups of neuropsychiatric symptoms, may be able to really improve that pain a little bit. I do think it really has to be scheduled, though. Trying to rely on patients who have significant cognitive dysfunction to use a PRN medication is going to lead to a lot of problems and undertreatment. And then on the sleep disorder side, I think starting with low-dose Trazodone and gradually increasing the dose of Trazodone as a really safe way of initially approaching the insomnia. And then only when it's a more refractory case do I reach for the high-risk medications. Like for pain, we're talking about opiates. I think there's a lot of very reasonable concern about using opioids in patients who have cognitive dysfunction. But if there is a really good reason to think that they have severe pain, like they have a past pain disorder, I think that just like with antipsychotics, there are definitely real risks to these medications. But at the end of the day, if we are improving someone's quality of life dramatically and the patient's medical decision maker is willing to take on those risks, then we're really doing the patients a favor. Dr Grouse: Now, another issue that you mentioned in your article, which I see a lot and often struggle with myself, is how and when to deprescribe certain types of medications such as cholinesterase inhibitors and memantine. Any tips or tricks to how to approach this?  Dr Weisbrod: My approach to this has also evolved a bit over the years. The new data that cholinesterase inhibitors may have a mortality benefit in patients with Alzheimer disease has changed my thinking a little bit. But there are still lots of situations where it's just too burdensome or patients seem to be having side effects. And so, I think about deprescribing. The most important thing in my mind is really thorough counseling before deprescribing with the patient's family and medical decision maker. I think that letting them know that we might actually be holding things more stable with the medication than we realize, there could be a flare-up, that we can resume the medication if that flare-up happens but we don't always guarantee getting back to the same point. I think having that conversation ahead of time will ward off some of the worst issues that you have afterwards. And then I think doing a taper of cholinesterase inhibitors over two weeks to a month is probably the most prudent because of some of the data about withdrawal and exacerbation of neuropsychiatric symptoms or cognitive worsening. Memantine, I think the data is a lot more shaky on withdrawal. And so, I think it's less important to gradually taper memantine. But I think that once again, just having the conversation upfront and letting the family know these are the things we have to look out for and these are the risks is going to be the most important. Dr Grouse: That's really helpful and a great strategy to take advantage of. Another, I think, really difficult topic that I wanted to ask you about was the discussion around nutrition and whether or not to consider putting in some type of a permanent tube for tube feeds. How do you approach that conversation? Certainly a difficult one.  Dr Weisbrod: Yeah, I think it's easily one of the most difficult conversations to have in the care of patients who have dementia. And there's so much emotion in the families when they're having this discussion. And I think really acknowledging there's a huge emotional piece of the conversation is one key piece. For families and caregivers, they're thinking, I don't want my loved one to starve to death. That's usually the most important thing in their mind. We have to address that concern in the conversation, or they're never going to get to a point of satisfaction with the decision that's being made. So, I think while there is still some controversy in the literature about artificial nutrition for patients who have dementia, the bulk of data indicates that it is not helpful for patients. It may exacerbate dementia, it leads to more restraint. And so, I think unless there's some reversible medical condition that we're just trying to do artificial nutrition to get them through, like, they have a stroke and we're expecting that their dysphasia is going to improve because of the stroke is going to heal. Those situations might be a good reason, but if we really think that the driving factor behind their dysphasia is their dementia, I think we should be guiding the families away from that. And I think that explaining that as dementia gets really advanced, the body is slowly shutting down. The body is not needing as much nutrition, and forcing more nutrition in has not been shown to help people who have dementia. Really putting it in that sort of language is going to help the families understand and be comfortable with that decision. I also think that it's really helpful to consider talking to families about what they can do and not have the entire conversation be about what we're not doing or not putting in a feeding tube for artificial nutrition. So, I think really good counseling about, we can do comfort feeding, we can expand what food we're giving the person who has dementia and really focus on foods that they really enjoy and not worry so much about the health and nutrition anymore. I think that focus on what they can take control of can also help make the decision easier for families.  Dr Grouse: I really like that approach. And I agree, it does seem that it being such an emotional decision with just so much a concern about this underlying feeling of not caring for their family member. I think that is a really great way to look at it  and to kind of start off that conversation. Now, I'd love to hear more about what drew you to this field when you first got into your career as a neurologist. Dr Weisbrod: I had an interesting journey to doing neuropalliative care. Definitely didn't know that's what I was going to do when I started neurology residency. At University of Rochester, we had amazing palliative care physicians that were involved in medical school, and so I got a little bit of exposure to it early on. Then when I was in neurology residency, I first of all realized that I really enjoyed making sure that what we were doing respected a patient's wishes. And so, as other people seemed to run away from those conversations, I was really drawn to them. And so that definitely made me realize that that might be more of the right field for me. But also, as I went through neurology residency, I really discovered that I love so many different things in neurology, and that made me not want to subspecialize and focus on a narrower set of conditions in neurology. So, doing palliative care fellowship was a really good way of getting a specialist tool set and expanding my knowledge in one area, but staying a neurologist, generalist. And I think it also really enhances a lot of the other things I do in neurology. It gives me a lot of additional skills on how to counsel patients and how to prepare for the future in general. I think there's a lot about just good bedside manner in palliative care education. I feel like it helped me become a better neurologist, and I decided that I really loved the palliative care piece as well.  Dr Grouse: Well, we're certainly all grateful that you found this aspect of your career and have been able to share the skills you've honed with us as well. And we really appreciate you taking the time to talk with us about your excellent article today, which I encourage everybody to read.  Dr Weisbrod: Yeah, thank you. It's been wonderful to be on, and I hope that people can take away a few small points from the article. Dr Grouse: Again, today I've been interviewing Dr Neal Weisbrod about his article on neuropalliative care in dementia, which appears in the December 2025 Continuum issue on neuropalliative care. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Former New York Times reporter and now independent journalist Alex Berenson is the author of “Tell Your Children: The Truth About Marijuana, Mental Illness, and Violence.”In this episode, we dive into the debate around cannabis and THC and President Donald Trump's recent executive order directing the Drug Enforcement Administration (DEA) to reclassify marijuana from a Schedule I to a Schedule III drug.Berenson argues that it's a bad move. Schedule I substances are defined as having high potential for abuse and no accepted medical use. Schedule III substances, in contrast, have medical uses and are regarded as having only moderate to low potential for abuse.Rescheduling marijuana sends the wrong signal, Berenson says: “Do we want to be a society that, in general, encourages drug use?”He believes the use of drugs should be stigmatized, including the use of marijuana: “In the U.S. we can't stigmatize. And not to stigmatize in this case, as in so many cases, means we can't be honest.”In my interview with Berenson, he provides an overview of the dangers of marijuana use and why these have increased dramatically over the last half-century.“Fifty years ago, cannabis that was in a joint that you smoked at Woodstock ... that might have been 1 or 2 percent THC, so a few milligrams of cannabis in a joint. ... When I was growing up in the ‘80s or in the '90s, it might have been 5 percent THC. Now, if you go into a dispensary ... the bud tender will sell you a product that is 20 percent to 30 percent THC, if it's flower cannabis,” he said.And if it's not smoked but vaped, then “that might be 95 percent THC. This is not a plant at all. It's just a chemical to get you high,” Berenson said. “Now you can walk around with this little device and inhale massive amounts of THC, and that really is a change that has made the product a lot more dangerous.”There is also a well-established link, Berenson says, between high-potency, frequent marijuana use, and severe mental health impacts such as psychosis and schizophrenia.There's even research suggesting THC causes heart damage. “There is a link to myocardial infarction, heart attacks, and that link is pretty strong. You can find papers that show a 3x increase over a multi-year period,” he said.But what about its benefits as a pain reliever? Berenson said that he was surprised to discover that placebo-controlled studies showed only small and short-term pain relief effects.“What cannabis and THC are really good at is enhancing sensation ... but if you're in pain, in the long run, enhancing sensation actually is not a good thing for you. ... And so the idea that cannabis is a substitute or a way out of our opioid problem is just not true,” Berenson said.“We as a society have to ... be honest with ourselves about what we are doing and what we are encouraging kids to do,” he said.In our wide-ranging interview, we also discuss the overprescription crisis in America, the dangers of SSRIs, psychedelics, and stimulants such as Adderall that around 10 percent of teenage boys are taking in the United States, and his thoughts on vaccine policy in America.Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

In this episode of The Truth with Lisa Boothe, Lisa digs into America’s mental health crisis in light of the tragic deaths of Hollywood icon Rob Reiner and his wife Michele — allegedly involving psychiatric medication struggles. Board-certified psychiatrist and former FDA medical officer, Dr. Josef Witt-Doerring joins Lisa to discuss the risks of psychiatric drug over-prescription, hidden side effects of SSRIs and antipsychotics, the impact on youth and developing brains, withdrawal challenges, and how Big Pharma influences the mental health narrative. If you’re curious about the long-term effects of antidepressants, the limits of current research, and how to approach mental health treatment more safely and effectively — this episode is a must-listen. Learn more about Dr. Josef HERESee omnystudio.com/listener for privacy information.

Allie interviews Dr. Josef Witt-Doerring, a psychiatrist and former FDA drug safety officer. He unveils the truth about Big Pharma and the detrimental side effects of medications for mental illnesses. SSRIs cause more harm than good; they blunt emotions, breed dependency, and often backfire long-term. Dr. Witt-Doerring advises patients to pursue holistic health that includes a balanced diet, sleep, exercise, and therapy. He and his wife have started TaperClinic, where they help people come off medications and find real solutions to their problems. Join us for an eye-opening discussion about the dark side of the pharmaceutical industry. Check out more about Dr. Witt-Doerring's TaperClinic here: ⁠taperclinic.com⁠ Buy Allie's book "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.toxicempathy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Timecodes: (00:00) Intro (09:45) Misdiagnosing Mental Illness (19:20) Drug Safety Officer (25:05) Corruption in Medical Academia (27:50) Wake-Up Call (34:35) Problems with SSRIs (46:00) Short-Term vs. Long-Term Medication (53:50) TaperClinic --- Today's Sponsors: PreBorn — Would you consider a gift to save babies in a big way? Your gift will be used to save countless babies for years to come. To donate, dial #250 and say the keyword BABY or donate securely at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠preborn.com/allie⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Good Ranchers — Give a reason to gather. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠goodranchers.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ to start gifting, and while you're there, treat yourself with your own subscription to America's best meat. And when you use the code ALLIE, you'll get $40 off your first order. EveryLife — Visit ⁠⁠⁠⁠⁠everylife.com⁠⁠⁠⁠⁠ and use promo code ALLIE10 to get 10% off your first order today!  Patriot Mobile — Switching to Patriot Mobile is easier than ever. Activate in minutes from your home or office. Keep your number, keep your phone, or upgrade. Go to ⁠⁠⁠patriotmobile.com/allie⁠⁠⁠ or call 972-PATRIOT, and use promo code ALLIE for a free month of service! Cozy Earth — Give the gift of everyday luxury this holiday season. Head to ⁠cozyearth.com⁠ and use the code RELATABLE for up to 40% off — just be sure to place your order by December 12 for guaranteed Christmas delivery. --- Episodes you might like:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ep 1189 | SSRIs Are Rewiring Babies' Brains — and Killing Their Moms | Guest: Dr. Adam Urato ⁠https://podcasts.apple.com/us/podcast/ep-1189-ssris-are-rewiring-babies-brains-and-killing/id1359249098?i=1000708507649⁠ Ep 821 | Why Antidepressants Don't Fix Depression | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-821-why-antidepressants-dont-fix-depression-guest/id1359249098?i=1000616890403⁠⁠ Ep 822 | The Big Money Behind Big Medicine | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-822-the-big-money-behind-big-medicine-guest-dr/id1359249098?i=1000617050991⁠⁠ Ep 1031 | Psychiatry Is Killing People | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-1031-psychiatry-is-killing-people-guest-dr-roger/id1359249098?i=1000661830317⁠⁠ --- Buy Allie's book "You're Not Enough (and That's Okay): Escaping the Toxic Culture of Self-Love": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.alliebethstuckey.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Relatable merchandise: Use promo code ALLIE10 for a discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.blazemedia.com/collections/allie-stuckey⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Week four of the Ending Well series lands right at the halfway mark. This episode is a look back over a three-year road (starting in 2022) of how God helped me fight inflammation, feel like myself again, and regain my "glow." This is not a weight-loss talk, not a quick-fix list, and not medical advice. It's a redemption story about healing from the inside out — spiritually, emotionally, and physically. "Beloved, I pray that you may prosper in all things and be in health, just as your soul prospers." — 3 John 1:2 Key Themes Redemption doesn't just cover salvation; it keeps working through sanctification and healing. Inflammation wasn't just a food problem — it was also a soul and nervous system problem. Real health change is slow, layered, and personal. Your timeline will not look like mine. The glow came as a byproduct of feeling better and living freer, not chasing beauty. Important Disclaimers This episode is descriptive, not prescriptive. Not medical advice. Always talk with a qualified professional for your situation. Do not try to do everything at once. This was a year of foundations plus a total three-year process. One percent better beats perfect overnight. The Story: How the Dominoes Fell 1. August 2022: Stepping Back From Fear-Driven "Crunchy" Culture I was drowning in rules, guilt, and constant fear of what might be harming me. The anxiety and striving became more toxic than the ingredients I was avoiding. First domino: I quit trying to do it all perfectly and started living with grace, budget reality, and peace. Lowering my standards for myself lowered my inflammation. "Come to me, all who are weary and burdened, and I will give you rest." — Matthew 11:28 2. October 2022: A Major Boundary With a Toxic Relationship I set a serious boundary with someone whose presence fueled self-hatred. Went no contact for about six months. The inner tape of shame and criticism began to quiet. I learned that giving up self-hatred is profoundly anti-inflammatory. Recommended resource mentioned: When to Walk Away by Gary Thomas (plus podcast interview) "Guard your heart above all else, for it determines the course of your life." — Proverbs 4:23 3. Early 2023: Changing How I Worked Out I stopped high-intensity workouts that were spiking cortisol daily. Switched to lifting heavy and slow, more functional strength training. Worked out less, recovered more. Energy improved, inflammation eased, confidence rose. Current favorite: Nourish Move Love workouts on YouTube. Big takeaway: exercise is a gift, not punishment. 4. February to May 2023: Going Gluten-Free and Cutting Back on Alcohol Grain Brain by Dr. David Perlmutter was a turning point. I tried going gluten-free (cold turkey, not ideal but it worked). Brain fog cleared, bloat dropped, inflammation noticeably reduced. Cutting alcohol alongside gluten made a huge difference. I don't need to understand every mechanism to honor what clearly helps my body. Reminder: everyone has a "thing" — gluten, dairy, sugar, alcohol, stress. Find yours with grace. 5. August 2023: Getting Off SSRIs After 15 Years A massive milestone with a full story in episode 267. For me, SSRIs were not helping inflammation or overall vitality anymore. The drop in facial inflammation from August to December was dramatic. I'm not shaming anyone on SSRIs — I was on them a long time. This was my path. "It is for freedom that Christ has set us free." — Galatians 5:1 What Actually Healed Me This part matters: the glow wasn't mainly from products. Lowering impossible expectations Creating boundaries Learning to like myself Getting out of fight-or-flight Moving my body in a gentler way Removing gluten and minimizing alcohol Walking in obedience even when it felt backwards Healing was spiritual and emotional first, physical second. "Be transformed by the renewing of your mind." — Romans 12:2 Simple "Glow Back" Skin Habits These are the practical, easy wins that helped the outside catch up to the inside. Dermaplaning at home Removes dead skin and peach fuzz. Skin care and makeup apply better. Big difference in glow and smoothness. Learn carefully through YouTube tutorials and use a quality razor. Stopping skin picking Picking was aggravating redness and irritation. I prayed about it and replaced the habit. New habit: brush my hair when the urge hits. Asking God for help in small things counts. Sponsor Spotlight: PreBorn A free ultrasound can double a mother's chance of choosing life. PreBorn offers ultrasounds plus ongoing support for mothers for up to two years. It costs 28 dollars to sponsor one ultrasound. Donate at preborn.com/speakeasy. Takeaways to Sit With If you're overwhelmed, start with one domino. God often heals from the root, not just the symptom. Your body listens to your beliefs. Peace, obedience, and self-kindness are deeply practical health tools. The goal isn't prettier; it's freer, healthier, and more whole. Reflective Questions What is one area where fear or perfectionism is inflaming your life? Who or what might need a boundary so you can heal? What small change feels like the next right step, not the whole staircase? How would your health shift if you treated yourself like someone God deeply loves? Closing Encouragement This glow-back story is really a "come back to life" story. It wasn't a sprint; it was obedience in baby steps. If you're in the thick of it today, don't despise the slow fade. God redeems years, bodies, minds, and hearts — and He's patient in the process. "He restores my soul." — Psalm 23:3

We know you're struggling. So we brought in the most soothing human on the planet-Therapy Jeff- to offer tips on how to get through Thanksgiving with your nasty family. In short, don't take the bait, find your family buddy, and if you are alone on the holiday, get yourself to a gay bar. Also, a woman who considers herself bad in bed wonders how she can find a "sex teacher." And, a woman wonders if she has her sub drink her pee while she is on SSRIs, will he ingest her meds? "Gobble" it up! Q@Savage.Love 206-302-2064 This episode is brought to you by Squarespace. They make it easy to build a website or blog. Give it a whirl at Squarespace.com/Savage and if you want to buy it, use the code Savage for a 10% off your first purchase. This episode is brought to you by Carafem, an abortion and reproductive healthcare provider that offers both in person care in Atlanta, Chicago, Washington DC and telehealth options for abortion pills by mail in 20 states. Carafem's team of licensed medical professionals provide personalized abortion care options focused on your needs, preferences, and values. Visit Carafem.org to learn more. This episode is brought to you by Feeld, a dating app where the open-minded can meet the like-minded. Download Feeld on the App Store or Google Play.

Methylene blue is one of the most misunderstood compounds in biohacking, yet it can upgrade your energy, mood, memory, and cellular resilience when you use it the right way. We are back again with another solo masterclass, and this one breaks down how to use methylene blue as a precision tool for brain optimization, longevity, and human performance while avoiding the dosing mistakes that create jitteriness, sleep disruption, or dangerous interactions. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey guides you through more than a century of research on methylene blue. He has been hacking this compound since the early 2000s and brings deep insight into mitochondria, neuroplasticity, metabolism, supplements, fasting, red light, ketosis, nootropics, and functional medicine. You will learn how methylene blue works inside the cell, how it improves electron transport, and why it appears in neurology, psychiatry, and anti aging research at the same time. This episode shows you how to test your own dose, how to stack it with light and ketosis for maximum effect, and how to avoid serotonin syndrome or sleep disruption. Methylene blue also touches nearly every major system that biohackers care about, which is why this solo masterclass shows you how it interacts with mitochondria, neuroplasticity, metabolism, sleep optimization, and long term anti aging pathways. You will hear how it influences redox balance, ATP production, brain optimization, and stress resilience, and how it behaves when combined with ketosis, fasting, creatine, NAD boosters, red light therapy, or other nootropics. Host Dave Asprey explains why methylene blue pairs well with certain supplements but clashes with psychedelics or SSRI medications, how it fits into functional medicine protocols for mitochondrial repair, and how to use data and wearable tracking to dial in your response. This episode gives you a complete framework to evaluate whether methylene blue belongs in your personal longevity strategy and how to use it with precision instead of guesswork. You'll Learn: • Why methylene blue acts like mitochondrial jumper cables and when it improves energy and mood • The exact signs that your dose is too strong, too weak, or in the Goldilocks zone • How methylene blue interacts with neuroplasticity, memory circuits, and cognitive resilience • Why psychedelics, SSRIs, and MAO inhibitors can create dangerous serotonin interactions • How to pair methylene blue with red light therapy, ketosis, creatine, fasting, or NAD boosters • The link between mitochondrial health, fertility, libido, and long term anti aging strategies • How to track sleep optimization, HRV, and performance signals to dial in your personal protocol • The difference between aquarium grade dye and pharmaceutical grade formulations • Why genetic testing for G6PD deficiency is essential before higher dose experimentation Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: methylene blue dosing, mitochondrial electron transport, Complex IV cytochrome c oxidase, redox cycling, MAO inhibition, serotonin syndrome risk, G6PD deficiency caution, neuroplasticity enhancement, dendritic spine density, mitochondrial stress adaptation, red light therapy stacking, cognitive performance optimization, ketone supported ATP production, nitric oxide independent focus boost, mitochondrial bottleneck repair, pharmaceutical grade methylene blue, sleep disruption signals, biohacking fertility support, oxidative stress buffering, functional medicine mitochondria repair Thank you to our sponsors! -BrainTap | Go to http://braintap.com/dave to get $100 off the BrainTap Power Bundle. -fatty15 | Go to https://fatty15.com/dave and save an extra $15 when you subscribe with code DAVE. -Zbiotics | Go to https://zbiotics.com/DAVE for 15% off your first order. Resources: • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Trailer 1:25 — Introduction 4:51 — History of methylene blue 7:38 — How methylene blue works 14:05 — Safety 17:53 — Dosing and timing guidelines 20:41 — Combining with red light therapy 22:41 — Quality and sourcing 23:17 — Dosing protocols 25:24 — Longevity and fertility effects 29:24 — Stacking options 32:10 — Common questions and FAQs 33:40 — Future research and wrap up See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.